

UNITED STATES DEPARTMENT OF AGRICULTURE

FOOD SAFETY AND INSPECTION SERVICE

+ + + + +

ADVANCES IN POST-HARVEST INTERVENTIONS  
TO REDUCE *SALMONELLA* IN POULTRY

+ + + + +

February 24, 2006

8:30 a.m.

The Loudermilk Center  
Atlanta, Georgia

FACILITATOR: DR. DANIEL ENGELJOHN  
Deputy Assistant Administrator,  
Office of Policy, Program and  
Employee Development, Food  
Safety and Inspection Service

PARTICIPANTS:

DR. SEAN ALTEKRUSE  
DR. PATRICIA BENNETT  
MR. DANE BERNARD  
DR. STAN BAILEY  
DR. MARK BERRANG  
DR. JEFF BUHR  
DR. KEN BYRD  
DR. JOHN CASON  
DR. PATRICIA CURTIS  
DR. MARTY EWING  
DR. RANDY HUFFMAN  
DR. LAURA HULSEY  
MR. LOREN LANGE  
DR. BARBARA MASTERS  
MR. DAVID McNEAL  
DR. JULIE NORTHCUTT

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

## PARTICIPANTS: (CONT.)

DR. ROBERT O'CONNOR  
DR. KEN PETERSEN  
DR. RICHARD RAYMOND  
DR. John Rice  
DR. RICHARD ROOP  
DR. SCOTT RUSSELL  
MR. MICHAEL RYBOTT  
DR. BRUCE STEWART-BROWN  
DR. ROBERT W. WILLS

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

I-N-D-E-X

<u>AGENDA ITEM</u>	<u>PAGE</u>
Validation Study Results Demonstrating.....	5
Control of <i>Campylobacter</i> in the Processing Environment	
A Study of the Relationship Between.....	19
Visible Fecal Contamination and Salmonellae Incidence in Broiler Slaughter Operations	
Use of Process Mapping in Poultry.....	27
Slaughter Systems to Support Multiple Hurdle Approach to Achieve Microbiological Reductions	
Plant Interventions: The Challenge of.....	41
Determining Best Practices for Microbiological Process Control	
<i>Salmonella</i> Interventions in the.....	55
U.S. Broiler Industry	
Control of <i>E. coli</i> 0157:H7 in.....	65
Beef Production	
Questions.....	84
FSIS Policy Initiatives to Encourage.....	103
Reduced <i>Salmonella</i> Positives in FSIS Regulatory Samples	
Adjourn	

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 P-R-O-C-E-E-D-I-N-G-S

2 (8:30 a.m.)

3 DR. ENGELJOHN: I'm Dr. Dan Engeljohn with  
4 the Food Safety and Inspection Service, and I'm going  
5 to facilitate this morning's presentation again.

6 We're going to get started and move  
7 through the six presentations that we have this  
8 morning. And I'll sort of gauge how you're all doing  
9 with regards to a need to take a break. But the  
10 intention is to do each of the six presentations, and  
11 then we'll have a break after that.

12 Our first speaker this morning is Dr.  
13 Richard Roop. He's senior vice president, science and  
14 regulatory affairs, with Tysons.

15 Correction here; I'm sorry. This is Dr.  
16 Robert O'Connor with Natural Chicken -- with the  
17 National Chicken Council. He has a veterinary degree  
18 from the University of Tennessee and a Master of Avian  
19 Medicine from the University of Georgia.

20 His work with the poultry industry has  
21 included laboratory diagnostics and production  
22 veterinary medicine, including breeders, hatcheries

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and grow-out. Most recently, as the director of  
2 quality and food safety for a commercial broiler  
3 company, he's worked extensively with processing  
4 plants producing ready-to-cook chicken products. And  
5 controlling *Salmonella* is a special interest area for  
6 him.

7 So welcome very much, Dr. O'Connor.

8 DR. O'CONNOR: Thank you very much for  
9 that introduction. Can you all hear me? Yes? Okay.

10 I am from Foster Farms. Foster Farms is a  
11 long way away from here. Foster Farms is the largest  
12 producer of poultry on the west coast. I think some  
13 people think I work in Guam, but actually I am part of  
14 the United States. The challenges, I would say, that  
15 we face on the west coast really are not that  
16 different from what you face here in the epicenter of  
17 the industry, which is the southeast.

18 What I'm going to talk about today is a  
19 validation study that we did at one of our processing  
20 plants in California. And in this talk, I'll review,  
21 you know, what was the objective of this validation  
22 study; what were the methods used; what were the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 results on a discrete step-by-step basis; and then  
2 what was the overall picture.

3 So really, just going straight to the  
4 objective, the objective really was to look at the  
5 process. And when I say the process, I'm really  
6 talking about first process or slaughter. And in that  
7 process, those steps that we felt could either reduce  
8 or eliminate or at least control microbes -- that's  
9 what we were trying to validate.

10 So we were looking at general microbial  
11 populations, your aerobic plate counts, your total  
12 coliforms, your *E. coli*'s. We were looking at  
13 *Salmonella* from a presence/absence standpoint. And we  
14 looked at *Campylobacter*, which --I have done other  
15 validation studies, but I had never looked at  
16 *Campylobacter*.

17 And in a way, I would say that I did this  
18 for this study in part because the district manager in  
19 California asked me. He wanted to know what about  
20 *Campylobacter*; what does your process do relative to  
21 *Campylobacter*. And since I really didn't have an  
22 answer, I said, Well, I'll just validate it. So I

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 added it to this validation study.

2 I will add, though, that looking at  
3 *Campylobacter* from an incidence and a numeration  
4 standpoint -- it does add a lot to the cost of a  
5 validation study like this. It was very costly to add  
6 *Campylobacter* to this study.

7 And that might -- I think it will make me  
8 in the future look at other validation studies and  
9 say, Can I use this validation study and extrapolate  
10 onto processes which are basically the same?

11 The other objective, I would say, in this  
12 study was to look at the individual intervention  
13 steps, the discrete steps, and say, you know, Are they  
14 working in and of themselves, or are they not working?  
15 Or what do I get from looking at individual steps?

16 And then the last objective really is to  
17 just look at the overall process and say, Does it work  
18 or not with regards to pathogen control?

19 We didn't actually do the validation  
20 study. And by that, what I mean is I farmed the  
21 validation study out to a third-party laboratory, the  
22 Institute of Environmental Health. I had done two

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 other validation studies with this group. I was  
2 confident of their work.

3 Quite frankly, it's easier to have someone  
4 else come in on the graveyard shift and do the  
5 sampling with their team versus you up at 2:00 a.m.  
6 doing the sampling.

7 I think the design of the study -- I was  
8 very confident with Dr. Stopforth, the Ph.D.  
9 microbiologist who led the team, that we were  
10 scientifically based; we were statistically based.  
11 The 95 percent confidence interval was there.

12 So in a way, I think a validation study  
13 that's performed by a third-party lab in and of itself  
14 adds confidence for me to the result.

15 Really what they did is they came in for  
16 five different visits. And on each visit, they took  
17 these five discrete steps in first processing, and  
18 they sample. And they sampled at each step at each  
19 visit 15 pre and 15 post carcass samples. So over  
20 five visits, we had 75 pre and 75 post, for a total of  
21 150 samples per step that we were validating.

22 The methodology they used involved carcass

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 rinses. And it was no different than that that would  
2 be used by the Agency when rinsing carcasses, looking  
3 at things like *Salmonella*.

4 In terms of the lab methodology, there was  
5 both enumeration, and there was incidence. So for the  
6 general microbes, your aerobes, your total coliforms  
7 and your *E. coli*, they did dilutions, and then they  
8 enumerated. For *Campylobacter*, they did the same  
9 thing. They diluted and enumerated.

10 For *Salmonella* and *Campylobacter*, they  
11 also did enrichment, prescreening, selective media,  
12 and then confirmation of culture results for  
13 positives.

14 So again, for *Salmonella*, there -- it was  
15 really two-pronged. We did both -- or not for  
16 *Salmonella*; I'm sorry. For *Salmonella*, it was  
17 strictly presence/absence. For general microbes, it  
18 was enumeration. And *Campylobacter* had both  
19 enumeration and presence/absence.

20 The next probably eight or so slides --  
21 they're going to look very similar, so once you get  
22 used to the background, you'll understand what we're

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 looking at. Really what you have here is each of the  
2 discrete steps. And I look at it in terms of the  
3 first slide is the enumeration, and the second slide  
4 is the incidence.

5 So the first slide is always going to  
6 contain your general microbes and the lab value that  
7 we found pre and post. So this would be your pre and  
8 your post. Your *Campylobacter* is the light blue. And  
9 again, that's enumerated.

10 So I think one of the things you can see  
11 from this initial slide is our levels of general  
12 microbes. If I looked at just aerobes, it comes in a  
13 little bit -- about four and a half. And one of the  
14 interesting things, I think, for me to note -- because  
15 I really didn't know what it was going to look like --  
16 is that the *Campylobacter* level at the New York was  
17 fairly low coming in. It was at half a log.

18 If I look at the discrete step and I say  
19 to myself, What effect did I have pre and post, I'd  
20 actually say, you know, I really can't speak to much  
21 elimination or reduction. I would say that I  
22 maintained control at each step at the New York wash.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1                   The next slide is the same step. It's the  
2 New York wash. But here's I'm just looking at  
3 presence or absence of *Campylobacter* and *Salmonella*.  
4 So this is an interesting slide just to note that from  
5 an incidence standpoint, I came in at 46 percent  
6 positive for *Campylobacter* and about 30 percent  
7 positive for *Salmonella*.

8                   There was a slight reduction of  
9 *Campylobacter* and about a 10 percent reduction for  
10 *Salmonella* at this step.

11                   Okay. The next step, which if you really  
12 look at the process is pretty far down the line from  
13 New York wash -- because the next step is IOBW number  
14 1. So you've gone through this evisceration. You've  
15 gone through inspection. You've gone through organ  
16 harvest. And now you're starting to clean the inside  
17 and the outside of the bird.

18                   And I think one of the things to note is  
19 that I actually already have a reduction from even my  
20 post New York wash number. My post New York wash  
21 number was above log four, and now I'm below. So  
22 there are actually some actions and some steps that I

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 didn't measure, but they're taken in between the New  
2 York wash and the first inside/outside bird wash.

3           And what I would say those are is the many  
4 nozzles and rinses that we have of the evisceration  
5 equipment, as well as, you know, just focused washes  
6 on some of the carcasses. And those focused washes  
7 would be with chlorinated water of 20 to 50 parts per  
8 million.

9           The *Campylobacter* -- and I'm really --  
10 that did not drop all that much from the post New York  
11 wash to this step. You're still at about half a log.

12          At this particular step, if I look at it on its own,  
13 did I eliminate; reduce or maintain -- again, for the  
14 general microbes, I would say I just maintained, but I  
15 maintained at a lower level than what I was at at the  
16 New York wash.

17           And there was a slight reduction that you  
18 could measure of *Campylobacter* at this step. For  
19 incidence of *Campylobacter*, we went down about 10  
20 percent. And the *Salmonella* was cut in half at this  
21 step from a presence/absence standpoint.

22           For the inside/outside bird wash number 2,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 which was the third step that we validated, again, we  
2 maintained, I would say, in the general microbe area.

3 And coming into this step, you can see that basically  
4 we were at zero for *Campylobacter*, and we maintained  
5 that.

6 From an incidence standpoint,  
7 presence/absence, we took the *Campylobacter* from 26  
8 percent to 14 percent. And the *Salmonella* hovered  
9 between 2 and 5 percent, which essentially -- 2 and 5  
10 percent really, in my book, is not that much different  
11 when I'm talking presence/absence.

12 The next step is the online reprocessing  
13 cabinet. And we did use trisodium phosphate in this  
14 cabinet. If you look at the enumeration numbers for  
15 microbes, this is actually where I can say you start  
16 to really see a decline in a discrete step. For  
17 *Campylobacter*, we maintained it at or close to zero.

18 Now, this is an interesting slide, because  
19 I think this speaks to the idea of enumeration versus  
20 presence/absence. If you remember, the *Campylobacter*  
21 incidence at the inside/outside bird washing were 2.  
22 Post that step, it was 14 percent.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Well, if I just look at incidence here,  
2 we're at 32 percent. So we might say, Well, what  
3 happened between IOBW number 2 and your online  
4 reprocessing cabinet? And that is the question that I  
5 asked when I saw this.

6 And I think I can answer that question, I  
7 guess, theoretically by saying when I look at  
8 incidence, presence or absence, I'm really only  
9 looking -- do I have the presence of one cell or maybe  
10 a hundred cells. I don't really know.

11 So what I really turned to was the  
12 enumeration data. And the enumeration data -- I'm  
13 sorry. The enumeration data for *Campylobacter* showed  
14 me that I had an extremely low level, and I maintained  
15 it in the OLR cabinet.

16 So from that standpoint, I was satisfied  
17 that there really wasn't an issue here, that looking  
18 at incidence, you know, might not be as all-telling as  
19 I might look at it if that's the only information I  
20 had.

21 From a *Salmonella* standpoint, incidence-  
22 wise, I reduced it from 16 percent to 4 percent.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           And the last step, really, that we looked  
2 at was the chiller. And this was a chiller that used  
3 chlorine and CO2 for acidification. And again, here  
4 with the general microbes, you actually do see a  
5 decline in the chiller. So I can say I had reduction  
6 of about a half log here in the chiller. And again,  
7 the *Campylobacter* was maintained at or very close to  
8 zero.

9           And interestingly enough, if I look at my  
10 incidence now for *Campylobacter*, you know, I'm at 23  
11 percent, and I drop to 14 percent. And I'm at 6  
12 percent for *Salmonella* and drop to 3 percent. I would  
13 still -- even those -- even though these numbers look  
14 very good for *Campylobacter*, I still think those  
15 numbers for enumeration tell me the story I want to  
16 hear, which is that I'm practically zero coming out of  
17 the chiller.

18           This is really the last slide, which I  
19 would say speaks to the idea of a multiple-hurdle  
20 approach, because this is the whole picture from New  
21 York wash through the chiller exit. But this is also  
22 a slide you have to have a little explanation for.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1                   Because this number here, these data  
2 points, they represent pre New York wash. And then  
3 the data points that follow -- they really represent  
4 the post New York wash sample combined with the pre  
5 sample of the next step.

6                   The solid lines represent your  
7 enumeration, and the dotted lines represent your  
8 incidence. So if I just look at my solid lines, I'm  
9 very satisfied with kind of a long gradual decline,  
10 you know, from here to here. If I look at my  
11 incidence curves, I do have some jogs upward here, you  
12 know, downstream in the process.

13                   But again, I kind of go back to the idea  
14 that, you know, if this is my *Campylobacter* incidence,  
15 this is my *Campylobacter* enumeration. And even though  
16 I have a slight jog upward here, I'm maintaining  
17 control. So really, to me, what this slide tells me  
18 is that my overall process, just by the pattern of  
19 decline, is in control.

20                   And if I were to look at it from an  
21 enumeration standpoint, my *Campylobacter* numbers are  
22 very good as we go through this process.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1           And I will probably use my general  
2 microbes as a proxy to my *Salmonella*, because I did  
3 not enumerate *Salmonella*. But I've got *E. coli*; I've  
4 got total coliforms in there, and I think I can use  
5 those graphs or those lines as a proxy.

6           So in conclusion, for this study I feel  
7 what we did is we validated -- we did validate  
8 changes. We validated reductions in microbes of log  
9 one and a half to two and a half. So I had over 95  
10 percent reduction in my general microbes.

11           My *Salmonella* incidence dropped from 30 to  
12 3 percent, so that's very good. And for  
13 *Campylobacter*, which -- again, that was sort of a  
14 point of interest for this study. I went from 46  
15 percent to 14 percent if I'm going to put an emphasis  
16 on incidence.

17           And I think this number is fairly  
18 accurate, because if you look at U.S. Poultry and Egg,  
19 their survey which they're doing of the entire  
20 industry -- and they are including *Campylobacter* --  
21 their chiller eggs incidence number runs about 20  
22 percent, I believe. So this 14 percent is in about

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 that range.

2 And in terms of load, what I saw was much  
3 less of a load coming in than I expected, but we  
4 maintained and really reduced that load. And I think  
5 that's a good thing.

6 I think individual interventions -- I  
7 think they're very important to look at. But what I  
8 saw was that up-front, you more or less plateaued.  
9 And your declines really occurred further out in the  
10 process, at the OLR cabinet and the chiller.

11 But I think overall, the biggest picture,  
12 you know, to look at is that last slide -- and to look  
13 at the pattern of that slide. And I think when you  
14 walk away from the pattern of that slide, that's when  
15 you really say, Do you have the process in control or  
16 not?

17 And I think from this validation study, I  
18 would say that, you know, in that plant the process is  
19 under control for pathogen reduction.

20 So appreciate the time, and I'll answer  
21 questions at the question and answer period.

22 (Applause.)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 DR. ENGELJOHN: Thank you very much,  
2 Robert. That was excellent in terms of providing some  
3 perspective of how to conduct a validation study and  
4 demonstrate that a processing operation works and  
5 where actually interventions are in fact effective.

6 Now Richard Roop will present. He's  
7 senior vice president of Tyson Foods. He's out of  
8 Springdale, Arkansas. And his role is with food  
9 safety, quality assurance, regulatory compliance,  
10 laboratory services, statistics, consumer relations,  
11 and animal welfare.

12 Welcome.

13 DR. ROOP: Thank you very much. I had the  
14 honor of speaking about fecal contamination today.  
15 And fortunately for me, several folks have already  
16 mentioned some of the studies that I'll reference in  
17 my talk, and so you'll see a couple of the same  
18 citations in my talk that you saw earlier.

19 The first thing I want to do is clarify  
20 what this is. This is a presentation assessing the  
21 relationship between pre-chill visible fecal  
22 contamination and the incidence of *Salmonella* on post-

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 chill carcasses.

2           What this is not. This is not a criticism  
3 of FSIS's original HACCP expectations or requirements  
4 relative to visible fecal material. And it is not a  
5 presentation recommending the elimination of zero-  
6 tolerance standard for visible fecal contamination.

7           The final rule, which went into effect May  
8 5, 1997, was published in the Federal Register in  
9 February 1997. And a couple excerpts from that final  
10 rule -- said that this zero-tolerance policy for  
11 visible fecal contamination is an important food-  
12 safety standard, because fecal contamination is a  
13 major vehicle for spreading pathogenic organisms such  
14 as *Salmonella* to raw poultry.

15           It further went on to say that fecal  
16 contamination is a reliable indicator of the likely  
17 presence of microbial pathogens, a food-safety hazard  
18 which all slaughtering establishments will necessarily  
19 address in their HACCP plans.

20           Additionally, critical control points to  
21 eliminate visible fecal contamination are predictable  
22 and essential components of the HACCP plan for all

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 slaughter establishments. For establishments' HACCP  
2 plans to be validated, they will have to achieve a  
3 zero tolerance for visible -- excuse me; a zero  
4 tolerance for visible fecal contamination at the point  
5 where carcasses enter the chiller.

6 Well, let me explain why this is  
7 important. In 1975, Blankenship did a study comparing  
8 the microbial quality of inspection-passed carcasses  
9 and condemned broiler carcasses. And his conclusion  
10 was, our results also suggest that *Salmonella*  
11 incidence associated with fecal contamination is no  
12 greater among contaminated carcasses processed through  
13 the final washer than it is for inspection-passed  
14 carcasses.

15 Dr. Jones from the University of Arkansas  
16 conducted a broiler study. It was actually done  
17 between February and May 1998. It consisted of 14  
18 processing plants from 3 separate integrators. And  
19 during this study, he looked at the relationship of *E.*  
20 *coli*, *Salmonella*, fecal-compliance citations and NRs.

21 Well, I have one slight correction. N was  
22 not a hundred. N was 1889, and there were a hundred

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 positives for *Salmonella*. The data was -- the *E. coli*  
2 counts in isolation and the *Salmonella* were all done  
3 using USDA methods, and they were aggregated and  
4 analyzed using SAS.

5 I've boiled the data down to one very  
6 simple slide here looking at the correlation between  
7 percent salmonella incidence, NRs for fecal  
8 contamination, and average *E. coli*. And the  
9 correlation between *Salmonella* and fecal contamination  
10 was .094, and for *E. coli* it was .102.

11 And for those of you that are not familiar  
12 with correlations, a perfect correlation is 1, and  
13 absolutely no correlation is zero. So the conclusion  
14 Dr. Jones made was that these data indicate the  
15 parameters have virtually no correlation with each  
16 other.

17 A notice was published in the Federal  
18 Register in 1997, and this is a quote from that  
19 notice. And I just wanted to highlight the one  
20 sentence here that preparation for implementation of  
21 HACCP system regulations has not changed the Agency's  
22 conclusions about the appropriateness of this standard

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 under the FMIA as well as PPIA.

2 In fairness to FSIS, this came out before  
3 Dr. Jones's study was published. But the point I want  
4 to make here is that these regulations and notices  
5 were out there. And obviously industry began  
6 implementing CCPs for zero tolerance.

7 So in January, all broiler establishments  
8 entered the HACCP era with a CCP for zero tolerance  
9 for fecal prior to the chiller. At that time,  
10 *Salmonella* numbers across the industry appeared to be  
11 trending downward.

12 And then in 1999, or about a year after  
13 the implementation of the CCP for zero tolerance, NRS  
14 for zero-tolerance deviations appeared to be trending  
15 downward, which makes sense. It got a lot of  
16 attention.

17 So people therefore concluded that the  
18 enforcement of zero tolerance, the resulting  
19 regulatory enforcement actions and the industry  
20 attention, was having the desired effect on broiler-  
21 carcass contamination.

22 But then something happened, as we all

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 know, and we saw a trend upward in *Salmonella*  
2 contamination. In 1994, a very large spike in  
3 *Salmonella* -- and everyone started scrambling for  
4 answers. So we initiated another study of the data --  
5 this was a non-published study, by the way -- looking  
6 at zero tolerance and *Salmonella* percentages post-  
7 chill.

8 We looked at the data from 36 different  
9 processing plants for zero-tolerance failures from  
10 1998 through 2005. And as you can see, the zero-  
11 tolerance failures did drop, and they pretty much  
12 leveled out. There's a slight increase there, but  
13 it's not statistically significant.

14 Same time period, *Salmonella*'s trending  
15 upward. Now, intuitively you'd say there's a  
16 correlation there, a negative correlation. Well, we  
17 ran the stats on that. And of course, these are the  
18 same charts just blended together.

19 We ran the stats on that and found that in  
20 three of the plants, there indeed was a negative  
21 significant correlation between *Salmonella* incidence  
22 and zero tolerance. Eighteen plants had a negative

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 correlation, but it was not significant. Twelve had a  
2 positive correlation, but it was not significant. And  
3 three had a positive significant correlation.

4 So what does that tell you? It's pretty  
5 random. And overall, statistically, there's no  
6 significant correlation between zero tolerance and  
7 *Salmonella* contamination.

8 So we concluded from this study that zero-  
9 tolerance failures -- we learned that they decreased  
10 about one zero tolerance per plant per year from the  
11 time the standard was set. But we also know that  
12 *Salmonella* increased since the year 2000. *Salmonella*  
13 percentages and zero-tolerance failures are not  
14 significantly positively related.

15 At about the same time, Cason published  
16 his article concluding the same thing on the effect of  
17 pre-chill fecal contamination on numbers of bacteria  
18 recovered from broiler-chicken carcasses, saying that  
19 bacterial counts on fecally contaminated carcasses  
20 halves were not different from paired non-contaminated  
21 carcasses after chilling.

22 So what's the overall conclusion here?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Well, *Salmonella* can and does reside in broiler feces,  
2 hence the FSIS's position on zero tolerance. However,  
3 the level of contamination is not significant enough  
4 to increase *Salmonella* incidence, or the process is  
5 adequate to reduce the level of contamination to that  
6 of non-contaminated carcasses.

7 I think the most important conclusion here  
8 is that it's important to focus on visible fecal  
9 contamination from a quality and a regulatory  
10 standpoint, but don't focus on visible fecal  
11 contamination in an effort to reduce *Salmonella*.  
12 Thank you.

13 (Applause.)

14 DR. ENGELJOHN: Thank you, Richard, very  
15 much. That was very telling and has a very important  
16 message in for everyone to actually hear and take  
17 account of. So I think we, the Agency, also are very  
18 interested in your presentation.

19 Our next speaker is Dane Bernard. Dane is  
20 the vice president of food quality and quality  
21 assurance at Keystone Foods. Dane's going to talk to  
22 us about process mapping in poultry slaughter systems.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1                   Just a note about Dane's background. I  
2 worked with Dane quite a bit on the National Advisory  
3 Committee for Microbiological Criteria for Foods. And  
4 prior to his work at Keystone, Dane was an officer  
5 with for food safety at the National Food Processors  
6 Association.

7                   So thank you, Dane. Welcome.

8                   MR. BERNARD: Thanks, Dan. And thanks to  
9 FSIS for organizing this meeting. I think it has been  
10 very timely and informative. And Dan, if you ever get  
11 tired of regulatory writing, I think you have a career  
12 in MC'ing. You've been doing a super job.

13                   I was asked to talk on process mapping in  
14 poultry slaughter systems in support of multiple-  
15 hurdle approach to achieving microbiological results.

16                   It's a lot of words there. But I think the bottom  
17 line is if you listened closely to Bob O'Connor's  
18 talk, which was an excellent depiction of how this  
19 works, there's really very little else for me to say.

20                   But I have 15 minutes, so I'm going to spend it  
21 anyway.

22                   What's a hurdle? This is a term that's

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 been around in certain areas of microbiology for some  
2 time. It's rather poorly defined. But as applied in  
3 this case, it's a barrier to microbial growth or a way  
4 of killing or removing microorganisms.

5 It's in fact everything lumped into one  
6 general term. Kill them, keep them from getting  
7 worse, keep them from being there in the first place.

8 All of those would qualify as what a hurdle does.

9 And multiple hurdles basically is what you  
10 do when you have a -- when you have no single  
11 intervention that can get you where you want to be.  
12 And we have no single intervention that we have found  
13 in the poultry industry that will get us into the zone  
14 where we want to be with *Salmonella* and other  
15 pathogens that may be there.

16 So it is in fact an approach which -- to  
17 get the kind of control -- the level of control that  
18 we need, we have to look at the entire process and use  
19 all the tools that may be at hand.

20 And so my definition -- since I could not  
21 find any that would fit, I made something up, as I  
22 normally do. Intervention. I would prefer to have

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 interventions defined as a specific treatment that we  
2 apply to produce a measurable level of reduction in  
3 the population of a target microorganism. It is  
4 something that we do -- a process that we intend to  
5 achieve a reduction with.

6 Well, on the other hand, a hurdle may be a  
7 step in the process that minimized contamination or  
8 reduces or prevents a situation from getting worse.  
9 Interventions would be hurdles. Hurdles would not  
10 necessarily be interventions.

11 Process mapping or line profiling. Well,  
12 what are we talking about there? It's sampling at  
13 selected points in the process where contamination  
14 levels can be assessed for the purpose of measuring  
15 microbiological status of birds against a specific  
16 target organism or class of organisms.

17 So what I'm going to present in terms of  
18 the actual information is based on data gathered by  
19 multiple companies in multiple facilities, each  
20 facility with multiple lines. And I want to thank the  
21 companies, most of whom -- who are here, for  
22 contributing data to this presentation. It came to me

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 in a blinded form, so I don't know whose data was  
2 whose.

3 And it also came to me in various  
4 different ways. Certain companies averaged their  
5 data. Some companies sent broad data tables. Some  
6 sent charts that I had to pick points off of. And  
7 some sent very detailed graphs.

8 So it was a bit of a challenge to look  
9 through that and decide how to bring this to you. So  
10 because of the differences in the studies and because  
11 of the differences that you'll see in the data, all I  
12 can bring you today as a result of those studies is  
13 some very general parameters.

14 But the point of the presentation is not  
15 to give you information in terms of the -- we've  
16 solved the issues, and this is what this step does,  
17 and this is what that step does. The point of the  
18 presentation is to introduce to those who are not  
19 already -- not introduced to this concept a tool that  
20 can help you assess your operation and a tool that can  
21 be used to judge improvements in an operation and  
22 determine where to go.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1                   These are the sampling points that -- this  
2 is a composite of all the sampling points that were  
3 presented to me pre scald. And this is an interesting  
4 one where the bird, feathers on, is whole-rinsed.  
5 Post scald, obviously after the scald, again, a  
6 feathers-on whole-bird rinse.

7                   Post picking. Post washing. Post rehang.  
8                   Post evisceration. Pre cropper. Pre inside/outside  
9 bird wash. Post inside/outside bird wash. And most  
10 plants have two IOBWs in line. Some plants actually  
11 sample in between IOBW 1 and 2, but the data that is  
12 going to be shown later is after IOBW number 2.

13                   Post online reprocessing. Post chiller.  
14 Certain plants submitted data on chiller water, and  
15 some that had after-chiller intervention submitted  
16 data taken on birds rinsed after the post chill  
17 interventions.

18                   The three that are here in yellow are the  
19 common sites that all companies sampled. And -- but  
20 the rest of them were not sampled by every company  
21 involved in submitting data for this presentation.

22                   The organisms tested for. Everybody did

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 test for *Salmonella*, and that was a presence/absence  
2 test in all cases. Everybody did test for *E. coli*,  
3 and that was an enumerative test. Other organisms  
4 include total coliforms, aerobic plate count, and  
5 *Campylobacter*. And some enumeration on *Campylobacter*,  
6 some positive/negative on campy. Excuse me.

7 And as I said, the common organisms that  
8 everybody tested for was *Salmonella* and *E. coli*, and  
9 those are the ones that I'm going to talk about as we  
10 go forward.

11 The interventions used in these multiple  
12 plants included -- and nobody obviously used all of  
13 these in any one plant. Some used a combination.  
14 Some did not. FreshFX. And I'm sorry; I don't know  
15 what chemical compound that is. I went to the  
16 website, could not find that. So I'm not familiar  
17 with that one.

18 Chlorine dioxide. Cecure, which is, we've  
19 heard yesterday, the cetylpyridinium chloride.  
20 Sanova, which is acidified sodium chlorite. Inspexx,  
21 which is peroxyacetic acid-based antimicrobial.  
22 Chlorine in the 20 to 50 parts-per-million range. And

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 acidification using sodium acid sulphate to reduce the  
2 pH to six and a half in combination with free  
3 available chlorine in the three and a half to five  
4 parts-per-million range in chillers.

5 And I'm sure I've probably left some out.

6 So if my colleagues who are here want to comment on  
7 their own operations in terms of interventions,  
8 certainly you're welcome to do so. But from the data  
9 that I had, this was as close as I could come to the  
10 interventions that were in use.

11 So with the differences that were seen  
12 plant to plant, I'm not going to attempt to draw any  
13 overall conclusions regarding process capabilities.  
14 By the way, no data was submitted regarding quality  
15 aspects of using any one of the particular  
16 antimicrobials, so I have no information to share with  
17 you in terms of the quality effects of any of these  
18 antimicrobials.

19 The data. You know, after looking through  
20 tables and tables, I wish I could bring to you a  
21 succinct presentation that had more interpretation to  
22 it. But the best I could do was put the minimum and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 maximum ranges that I found from all the studies at  
2 each of the sampling points where there was sufficient  
3 data to report.

4 I did not include in the charts any data  
5 point which had less than four sets of data submitted  
6 with it. I did not report on any data-sampling point  
7 where only one company submitted data from that  
8 sampling point. So the number of sampling points that  
9 you see here is not as comprehensive as the list I  
10 showed you earlier, but the difference is because of  
11 the data gaps that were there.

12 It would be a misinterpretation of the  
13 data to look at the maximums on *Salmonella* and say  
14 that nothing happens before the online-reprocessing  
15 step. If you look at the maximums only, you may get  
16 that impression. But if you look at the minimum,  
17 clearly there is some things going on earlier than the  
18 online reprocessing.

19 And if you remember the data curve that  
20 Bob showed you in his presentation, you'll remember  
21 that he did show a steady decline across the process.

22 And in fact, most plants' data did show a steady

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 decline across the processing steps. And there are a  
2 couple of exceptions that I will talk about earlier.

3 This is the number of plants that were  
4 included in that particular data point. I'll call  
5 your attention to this one, post wash. We had one  
6 outlaw plant that -- the first sampling point they  
7 listed was post wash, and they came in at 7 percent.  
8 And that's the lowest. And of course that lowered the  
9 curve on the rest of us. But it is there, and it is  
10 what it is.

11 I will say that most of the other plants  
12 would have been somewhere in here, with some  
13 exceptions. Obviously, we had one or two that were  
14 well above that. But most of the plants were kind of  
15 in the 10 to 20 percent range at that particular  
16 point.

17 Post inside/inside bird washer. Again, I  
18 ask you not to interpret these points as being  
19 industry averages. They simply are not.

20 Okay. Moving along. A lot of *E. coli*  
21 counts, minimum and maximum log *E. coli* counts. Bob  
22 did a very good job of explaining to you the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 differences that you can see when you're looking at  
2 percent prevalence, which we had on *Salmonella* which  
3 was in the graph before, versus counts.

4           You'll see a steadier decline in count  
5 reductions on those organisms that we can enumerate  
6 than you're going to see with the percentages as we do  
7 on the prevalence data with *Salmonella*. I did not put  
8 a graph together, a line graph on the *Salmonella*,  
9 simply because it would have been a misrepresentation  
10 of the data.

11           The *E. coli* counts, on the other hand,  
12 seem to show more of a pattern of a steady decline  
13 across the process. And again, you can look at the  
14 minimum and maximum log counts that we saw here. And  
15 in most cases, we were getting down to very decent  
16 levels here at online reprocessing.

17           And I apologize that these lines are  
18 probably not very visible to those of you in the back.

19           My inability to enhance lines in Excel is the problem  
20 here, not the data. But I did put a graph on the data  
21 from the previous slide just to give you an idea that  
22 even when you agglomerate data, as I had to do here,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you're seeing a steady decline across the process.

2 On an individual-plant basis, you'll see  
3 data, like as Bob presented to you earlier, that'll  
4 show you a much more clear picture of the lines.

5 So why go to all this trouble? And I know  
6 that my poultry colleagues have probably already tired  
7 of hearing the beef analogy, but for those of us who  
8 wear both hats and went through, quite a bit the same  
9 issue with beef.

10 We found on the beef side that the next  
11 intervention came along, and we were under pressure to  
12 do improvements, and we would put it in. And it's  
13 kind of like cocking the shotgun and firing off, and  
14 you hope you hit it. And sometimes we did, and  
15 sometimes we didn't.

16 And it really was not until we began to do  
17 this type of study in the beef industry that we began  
18 to have a baseline by which we could judge the  
19 effectiveness of the interventions, by which we could  
20 judge whether the interventions were themselves not  
21 working or whether it was a certain other part of the  
22 process before the intervention that wasn't working.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           And it was said yesterday that none of the  
2 interventions will give you a complete reduction in  
3 microorganisms. And it was said yesterday that if you  
4 overload an intervention by feeding to it too many  
5 organisms, it won't work as well.

6           And until you do the line mapping, you  
7 don't know how one step is affecting the next which is  
8 affecting the next. So process mapping provides the  
9 baseline for assessing microbiological impact of any  
10 anticipated changes that you may want to make.

11           I will also show areas where immediate  
12 improvements can be made. If you go in and you know  
13 something should be performing better than it is  
14 because it's designed to perform better than it is,  
15 and it simply isn't, then you have a basis to go in  
16 and take a look at that particular step in the  
17 process. And it'll also provide a basis for judging  
18 the effect of individual process adjustments.

19           In summary, some preliminary observations  
20 on the data. No one intervention was universally  
21 effective. We still have a good deal of  
22 unexplained -- but I do not personally think it is

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 unexplainable -- variation in processed birds.

2 Obviously we have some variability in the  
3 birds themselves and some variably in the processes  
4 that we have yet to define. But I -- as I said, I  
5 think with more data we will find out that those are  
6 definable.

7 In general, *Salmonella*, *E. coli*,  
8 coliforms, campy and the aerobic plate counts declined  
9 throughout the slaughter process with two notable  
10 exceptions. We've already heard about picking, and I  
11 think it was fairly uniform that counts and things  
12 went back up at picking. Some in certain areas --  
13 they seemed to go up more than others. But it's a  
14 continuing opportunity.

15 And I -- after yesterday's rather pointed  
16 questions on water chilling, I wish I hadn't put this  
17 one in there, but it's a reflection of the data. It  
18 is not universal in the data that chilling seemed to  
19 cause counts to go back up or contamination  
20 back up, but it was there probably more frequently  
21 than I would have expected at this point in time.

22 And I think we know how to manage chillers

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 better than we ever have. And it's just a reminder to  
2 my industry colleagues not to take our ball -- our eye  
3 off the ball relative to this particular processing  
4 step.

5 I urge you to have caution when comparing  
6 *Salmonella* prevalence to reductions in counts of other  
7 indicators. Bob's already covered this very well.  
8 But we need an inexpensive way to enumerate  
9 *Salmonella*. It would help us a great deal.

10 Right now, using the MPN method, it costs  
11 about 200 to \$300 per sample to do a good *Salmonella*  
12 enumeration. It simply doesn't lend itself to the  
13 type of online controls or quick turnaround that we  
14 would like to have to be able to better assess our  
15 process. And I know there are some methodologies on  
16 the horizon. We look forward to those.

17 And for my micro colleagues, I apologize  
18 for this stand-in enterobacter here. I know that you  
19 all realize that's an 0157:H7 instead of a *Salmonella*,  
20 but I just simply didn't have a *Salmonella* to plug in  
21 there when I needed it at midnight. So thank you very  
22 much.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 (Applause.)

2 DR. ENGELJOHN: Thank you, Dane. That was  
3 very informative as well.

4 Our next speaker is Dr. Bruce Stewart-  
5 Brown. He's vice president of Food Safety and Quality  
6 for Perdue Farms. He's had experience with the  
7 poultry vaccine industry -- and as well as fine-tuning  
8 health programs for Cornish, broiler, roaster and  
9 primary-breeder operations.

10 Since '99, being at Perdue, he's  
11 coordinated health programs for all operations and is  
12 responsible for company-wide activities at Perdue.

13 Welcome.

14 DR. STEWART-BROWN: It's nice to be here.

15 If I was to say in my way of thinking what we're  
16 trying to do or trying to figure out is we need four  
17 or five ways in the plant to get a 50 percent  
18 reduction. And let's say you bring a hundred percent  
19 on -- in on feathers, which -- I'd like that not to be  
20 the case. We're working hard for that not to be the  
21 case.

22 But having said that, when we've looked at

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 the live-sign operations and looked at ceca in the  
2 chicken house, we have some operations that run close  
3 to 10 percent positive ceca in the birds in the  
4 chicken houses. That's low. That's really low.

5 And where only 30 percent of those houses  
6 are positive for *Salmonella* at processing -- and yet,  
7 when they go to the processing plant and you do the  
8 feather rinse pre-scald, they're a hundred percent  
9 positive on the feathers.

10 Now, I would say average in the ceca and  
11 the -- in the chicken house might run about 40 percent  
12 positive ceca, at least in our experience. Now, I'd  
13 rather take the 10 percent positive ceca, even if I'm  
14 going to get a hundred percent positive feathers,  
15 because I think the interventions will work better,  
16 because I would guess through enumeration you'd  
17 understand that there's less *Salmonella* they're going  
18 to have to deal with.

19 But let's say we don't have enumeration  
20 right now, and we have strictly this yes/no. You've  
21 got a hundred percent positive feathers or 90 percent  
22 positive feathers. Let's say you got four 50 percent

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 reductions. Well, that's a hundred to a 50. That's  
2 one. Fifty to 25. That's two. Twenty-five to 12 and  
3 a half. That's three. Twelve and a half to six and a  
4 quarter. That's four.

5 That -- six and a quarter percent with  
6 four 50 percent reductions. Another one gives you  
7 three and an eighth. That's assuming you have nothing  
8 in the process that made it go up. Let's say that we  
9 understand from picking you're probably going to have  
10 a 50 percent increase or could have a 50 percent  
11 increase.

12 Now, if you were hoping you had four and  
13 knew you had four, but you got this picker, you better  
14 get the fifth. So if you said of all the stuff that  
15 everybody's talked about this morning, done really  
16 well, worked really hard on this mapping -- we need  
17 five places to get 50 percent reductions in *Salmonella*  
18 to be at three and a quarter or six and -- three and  
19 an eighth or six and a quarter, something like that.

20 And that's probably a big stretch with all  
21 the mathematics and stuff. But once you look at the  
22 mapping, I think you'll start to think like that. I

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 need some places where I get 50 percent drops. How  
2 many do I have?

3 Well, we talked about these quite a bit,  
4 all these processes, and these talks flow really well.

5 A lot of us worked hard, threw our data into a big  
6 pot, tried to work on exactly what we can get done,  
7 scald or pick or New York, rehang, IOBWs, OLRs,  
8 chillers and post-chill dip or spray.

9 So of all those places, I want nothing  
10 that goes up, and I want four or five places where it  
11 drops in half.

12 If you said, though, really, of these, how  
13 many do I really have designated process control for  
14 *Salmonella* -- I got a lot of process control for  
15 temperature. I got a lot of process control for  
16 fecal -- presence or absence of fecal or ingesta.

17 But if you said how many have I really  
18 worked out the process control processes -- and do I  
19 measure them and do corrective actions on -- as it  
20 relates to *Salmonella*, well, it's a little bit  
21 disappointing in the end.

22 And I would say I believe some of us have

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 it in other places, but the places where we got it the  
2 most are OLR and perhaps on the post-chill dip or  
3 spray. We have a thing we can measure that makes us  
4 comfortable that that will give us that 50 percent  
5 reduction.

6 Now, some of you might say, Well, I think  
7 some of those interventions might give us more than 50  
8 percent reduction at times. Well, they might, but if  
9 you said I want it consistently; I want it all the  
10 time; I want it to be dependable as much or all the  
11 time as I can have, then I think a 50 percent  
12 reduction is probably asking the right question. To  
13 ask for something more than that's probably not  
14 dependable over time.

15 So why is it that that's all we know?  
16 Well, first of all, I'm saying why is it that we only  
17 know real good process control for OLR post chill?  
18 Well, one is it's microbiology. And when you get into  
19 it -- as Dane and Bob and Rick have put some  
20 numbers -- and I know numbers were put up yesterday  
21 also.

22 There's a lot of variation once you get

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 into it. You have to do multiple days, multiple time  
2 periods. Your process -- to get an idea of how the  
3 process performs, it takes quite a lot of dedication  
4 of time and resources. And you got to be prepared to  
5 knock it with numbers to get the variation such that  
6 you can understand it.

7 Every plant's different. Everybody  
8 knows -- I'm sure all of you know that a plant as it  
9 was designed when it was built is phenomenally  
10 different than how it's done today. Matter of fact,  
11 if you go in today and then come back in six months,  
12 how many of you would say that the plant's probably  
13 made a few changes since then?

14 I know in my experience you have got to  
15 stay after it to understand all the changes that might  
16 go on in a period of time. And process controls in  
17 place are generally aimed at things that we've aimed  
18 at because of good reasons in the past, which are  
19 temperature and fecal and ingesta and those kinds of  
20 things.

21 So what needs to be done? We need to  
22 identify the potential variables. That's been

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 described in a number of different talks -- develop a  
2 dependable way to measure them.

3 Dependable. That's a -- it doesn't mean  
4 we're having somebody run out and put, for instance,  
5 chlorine -- the best way is not generally to run out  
6 and run a paper test every so often. Although the  
7 state of the art of chlorine measuring and different  
8 ways has got to go so that we can depend on the data  
9 and get it on a routine basis.

10 Measure all the variables. But one of the  
11 things that really frustrate our folks, as you guys  
12 know, is that if you say, Here's all the things that  
13 are important; measure them all, and I want to know if  
14 we ever deviate off what all this list -- is what --  
15 I'm going to give you a laundry list of things I think  
16 we need to do and then make sure it's all there.

17 Well, in fact, there's a few of those that  
18 are more important than others, and we need to know  
19 which ones those are. And then we of course need to  
20 implement it.

21 How variable is it? I took some of the  
22 data that Dane presented and did it a little different

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 way. And I said, I'm going to take ten scalders, six  
2 pickers, 12 IOBWs, 12 OLRs, 60 birds in a line, 60  
3 birds before they go through that, and 60 birds after,  
4 spread over five days. So ten -- six sets of ten. Do  
5 yes/no on *Salmonella*.

6 And what you see is -- I need to take a  
7 second to explain this. This means that there's a  
8 *Salmonella* reduction of 75 percent or more. So the  
9 *Salmonella* went down that much. If it went this way,  
10 the *Salmonella* increased to a hundred percent. So if  
11 it was 20, it went up to 40. If it was 50, it went up  
12 to a hundred or more.

13 These are the interventions I picked to  
14 put on this to show you how this might look. And OLR  
15 cabinet -- and these are the number of those OLR  
16 cabinets that performed at that level of *Salmonella*  
17 reduction or increase.

18 Well, here's one OLR cabinet that's  
19 relatively disappointing, between 25 and 50 percent  
20 reduction. Here's nine OLR cabinets giving me what I  
21 would hope is at least a 50 percent reduction.

22 The variability of these scalders is

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 disappointing, because I need the scalders to give me a  
2 50 percent reduction. And yet I got two up here that  
3 are not doing anything. If anything, they're going to  
4 the high side. I got one phenomenal one down here  
5 giving me a better than 75 percent reduction. I've  
6 got too much variation in these scalders.

7 I got pickers increasing it, of course,  
8 and you've heard that before. I got one picker 75  
9 percent to a hundred. Now, one of the things is I had  
10 to pull some pickers out, because it's not fair to say  
11 a picker kept it even if it went in at a hundred and  
12 came out at a hundred.

13 That would have said the picker didn't add  
14 to it. Well, I wouldn't say that picker's doing a  
15 great job because it kept it at a hundred. So I had  
16 to take out some pickers that showed you gave a decent  
17 number going in.

18 So let's say a scalders' working good.  
19 You're going 40 percent into the picker. Well, a good  
20 scalders -- a great scalders, in my mind, would have  
21 kept it at 40. That would be awesome. I'd like some  
22 scalders that would keep -- I'm sorry; pickers that

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 would keep it at 40.

2 For instance, if you -- here's my comment  
3 overall. I think if we're going to get five things  
4 that cause a 50 percent reduction -- I like the  
5 opportunity. I think we've got the processes for  
6 scalders. I think we got a good OLR opportunity.  
7 That's a relatively good one to do.

8 Chillers. We do know enough about  
9 chillers. However, every chiller you get into's way  
10 different. And I don't think that we're defining  
11 enough of the variables associated with chillers to  
12 make them dependably give you a 50 percent reduction  
13 day to day. We've got a lot of work to do to get that  
14 done.

15 So scalders, OLR, chillers. One of the  
16 underutilized or -- we need IOBWs to give us a 50  
17 percent reduction. And if you said, How is IOBW going  
18 to give you a 50 percent reduction -- well, we've got  
19 to get away from the current control process which  
20 might be -- zero fecal and maybe chlorine are the two  
21 things that judge an IOBW's success or failure.

22 And if you look at why a plant messes with

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 an IOBW, why we mess with an IOBW, it's because it's  
2 not doing what we want it to do generally on a fecal  
3 issue. You change the nozzles, change the pressure  
4 maybe. But what we end up monitoring is basically  
5 success on fecal and maybe chlorine.

6 What it could be is chlorine level, how  
7 much water at what pressure with what spray pattern at  
8 what capture rate and how much coverage. A lot of  
9 details to get to on IOBWs to make them a successful  
10 50 percent reduction tool.

11 I think they can do it, but I don't think  
12 they can do it just looking at process control that's  
13 up in this area.

14 I did this just for fun. If you said --  
15 took all those plants and give me the best of -- I  
16 want the best scalding, picker, New York dress, IOBW,  
17 OLR, chiller, post chill. Well, they happen to --  
18 unfortunately, there are none in the right -- they're  
19 all over the place.

20 So I took -- I had to pull it from plant  
21 1, plant 2, plant 3. Actually, plant 3 had two of the  
22 best. Plant 4's got the best OLR. Plant 2 is here on

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 picker and chiller. And post chill on plant 5. Well,  
2 we got 82 percent reduction in that scalding. I want  
3 more of those.

4 This is the best we can expect from a  
5 picker, unfortunately. We got work to do on pickers  
6 as an industry to get pickers to stay -- could they at  
7 least keep it even? That would be awesome.

8 New York dress. I don't know what to  
9 expect from New York dress, but I need something to  
10 come from New York dress. I believe we need something  
11 to come from New York dress. Well, at least in this  
12 case, down 33 percent.

13 IOBWs got to do better consistently. OLR  
14 good. Chiller good. Can be all these real good --  
15 that'll get you to zero percent if you had the best  
16 of. Matter of fact, you don't need all that to get  
17 some pretty awesome numbers.

18 Unfortunately, I don't have all this in  
19 one plant. I'm not sure exactly how to reproduce it.

20 But that's what I would call this best-of action  
21 plan, which is if you don't know all the process  
22 control things you need to do, one of the things is

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you go judge them all.

2           Go judge and find what works the best.  
3 Then define that. Then take that definition and move  
4 it around. And that's what we as an industry are  
5 trying to work on. It's frustrating. It takes a lot  
6 of time. You got to do a lot of numbers.

7           You got to work together really hard,  
8 because somebody's best of is -- not everybody has  
9 best of every piece of that. It takes a lot of work  
10 to find that. So find the best, move it around, put  
11 process control in place that assures it stays in  
12 control, check it, verify it, adjust the process  
13 control through continuous learning.

14           And I can guarantee you once you get it  
15 defined, you will get the process control in place.  
16 And you guys all know this. The plant for good  
17 reasons will change process. That means that whole  
18 thing has got to go again, because something that was  
19 best of now becomes average, because a change was made  
20 in the process for good reasons.

21           It just means it's a really ongoing  
22 energy-sapping resource-depending activity. But all

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 real good work. I'm for it.

2 Basically, that -- the message is we need  
3 four -- at least four, if not five, 50 percent  
4 reductions. We need to figure out how we can get rid  
5 of any place where it goes up. We need to find best  
6 of, define it, move it around, talk to each other  
7 about it, get more of those going. We'll be  
8 successful with that.

9 (Applause.)

10 DR. ENGELJOHN: Thank you very much. It  
11 was very informative.

12 We have a change in the program. Dr. Beth  
13 Krushinskie was supposed to come and make a  
14 presentation on *Salmonella* interventions in the U.S.  
15 broiler industries, but we are aware that she had a  
16 conflict which was not timely in the sense that she  
17 really needed to take care of the other issue.

18 And so today we have a stand-in who's  
19 capable of presenting the information that Beth was  
20 going to present. We have John Rice. John is with  
21 Sanderson Farms. And he's a native of Georgia, a  
22 graduate of University of Georgia and Clemson

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 University. He's out of Mississippi. And he's  
2 responsible for quality assurance, food safety, and  
3 laboratory operations.

4 Welcome, and thank you, John.

5 DR. RICE: Thank you, Dan.

6 Well, if I'd known I was going to present  
7 this talk, I might have packed a tie and might have  
8 packed a razor. Those that really know me well know I  
9 might have worn the tie, but I wouldn't have used the  
10 razor.

11 Anyway, this presentation -- I had the  
12 opportunity to look it over once last night. But this  
13 is a survey that was done of the industry. It was  
14 voluntary. And Beth is just summarizing the results  
15 here. If there's any conflict between what I'm saying  
16 and what you're reading, take what you're reading as  
17 the gospel truth, because I might misinterpret  
18 something.

19 So we got to look at the -- we're going to  
20 have an overview, look at some results and industry  
21 comments that were made -- and also a summary there.

22 This is a long ways from being a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 scientific survey, because it was voluntary, and it is  
2 not statistically valid, not a random sample, because  
3 only the results we have -- are those that voluntarily  
4 responded.

5           Is it meaningful? Yes, probably it is,  
6 because I feel like we got comments from people that  
7 were using things that they thought were effective.  
8 And also, we got some comments from people that were  
9 using things that they felt were maybe not quite so  
10 effective. But it does pretty well represent the  
11 common practices that are currently being used in the  
12 broiler industry in the States.

13           Now, this did cover a hundred broiler-  
14 processing facilities, eight integrated companies.  
15 And we had five treatment points that were mentioned,  
16 the pre-scald brushes to remove debris, online  
17 reprocessing, the chiller, the chiller acidification,  
18 and post-chill treatments.

19           First question was do you have an  
20 antimicrobial intervention at any of these locations.

21           And the answers were, in most case, yes. And here  
22 are the percentages where there was *Salmonella*

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 intervention in place of these hundred plants.

2 At 18, they had something at the scalding.

3 Eighty-six had online reprocessing. Ninety-three had  
4 some intervention at the chiller. Twenty-one had an  
5 acidification program for the chiller. And 12 had  
6 some type of post-chill treatment.

7 All right. If so, what product or what  
8 compound are you using as your intervention? In the  
9 scalding, we had two things mentioned. One of  
10 hypochlorous acid, and the other was sodium hydroxide  
11 to raise the pH.

12 And I really don't have any information as  
13 to exactly what reduction you would get with sodium  
14 hydroxide raising the pH. I have heard that you need  
15 to get the pH up to about 8.5 or 9 to have an effect.

16 And of course, we did have a mention earlier  
17 yesterday about a low pH having an effect. So either  
18 a very high or a low pH may have an effect.

19 And then also we had some comments that we  
20 used in sodium hydroxide in the scalding --

21 Now, scalding interventions. Out of 18  
22 that had, we had half of use using hypochlorous acid

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and half using sodium hydroxide.

2 The online reprocessing. As you're aware,  
3 there are a lot of compounds that have been approved  
4 by USDA for this purpose. And I'm not going to go  
5 through and read all these to you, because they've  
6 already been mentioned previously.

7 Here is the -- there' the incidence of the  
8 different types of online-reprocessing interventions.

9 The most popular has been sodium chloride, followed  
10 by TSP, chlorine dioxide, and hypochlorous acid. And  
11 then you get into the rest of them that have been used  
12 in just a few plants.

13 And then we looked into the chemicals that  
14 are used in the chiller itself as antimicrobials.  
15 There are five products mentioned, bromine, chlorine  
16 dioxide, hypochlorous acids, monochloramine, and  
17 peracetic acids.

18 And this is showing the number of plants  
19 that are using each of these compounds. By far, the  
20 majority of plants, 72 out of 93, were using  
21 hypochlorous acid in the chiller, followed by 18 using  
22 peracetic acid.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           And then we get into chiller acidifiers to  
2 reduce the pH to make the chlorine more effective.  
3 Had two mentioned, carbon dioxide and citric acid.  
4 And I -- in addition, I know of at least one other  
5 plant in the country that is using food-grade sulfuric  
6 acid to reduce the pH of their water.

7           This is a situation where their -- they've  
8 got a lot of dissolved solvents in the water, and the  
9 water's very hard. And it is work -- with the  
10 university to determine what would be the best. And  
11 they did look at chlorine dioxide. They did look at  
12 citric acid. But they decided that sulfuric acid  
13 would work better. And the result at that plant is --  
14 I 've been told have been very good.

15           And here, of these plants that are  
16 acidifying the chiller, most of them are using CO2, in  
17 fact, 90 of those. And then ten were using citric  
18 acid.

19           Post-chill treatments. We have three  
20 compounds mentioned here, acidified sodium chlorite,  
21 chlorine dioxide, and hypochlorous acids. Well, here  
22 is the numbers of plants that are using these. Most

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 of the plants -- 67 that are using sodium chlorite, 25  
2 using chlorine dioxide. And I believe this is eight  
3 using hypochlorous acids.

4 Third question we had. What are your  
5 overall impressions of the efficacy of these  
6 interventions? Several comments. It is difficult to  
7 say which are most effective or least effective  
8 because of the many variables in the plant that affect  
9 performance.

10 And this includes seasonality. It  
11 includes the incoming load on the bird, which we still  
12 don't have a really good way to measure. Water  
13 quality and also the different types of equipment that  
14 Bruce Stewart-Brown was talking about -- that you  
15 don't always have the best of everything in one plant.

16 There were also -- you got these other  
17 things that are listed, your wastewater impact, your  
18 export country restrictions. If you're shipping to  
19 some countries, you can't use some of these  
20 interventions.

21 We also had comment that yes, multiple  
22 hurdles are required. None of these interventions

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 will work without attention to the whole process. And  
2 a very important point is regardless of what some of  
3 your suppliers are trying to sell you, you can't just  
4 put these things in and forget about it. Somebody has  
5 got to be paying attention to what is going on,  
6 because you can have problems with the system that's  
7 feeding your chlorine.

8           You can have problems with the system that  
9 is acidifying your chiller water. There's even been  
10 situations that -- what I found out in one of our  
11 plants -- they were using a unit to measure the free  
12 available chlorine that was not working properly. So  
13 all these things you need some controls on.

14           Comments here. A lot of people feel that  
15 the high pH in the scalding does appear to be  
16 effective. And also, some feel the chlorine dioxide  
17 in the chillers is not very effective. Something we  
18 had discussed earlier in a meeting in Washington is  
19 that the limit of five parts per million free  
20 available chlorine in the red-water return needs to be  
21 reassessed.

22           We feel like --that this is a point where

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 we could get better control if we were allowed to go  
2 up a little bit on this. Because you really can't aim  
3 right at five, because sometimes you're going to be  
4 above that. And when you're above five, then you're  
5 above the limit that's allowed in USDA's policy. So  
6 if we could get a little higher level of chlorine into  
7 the chiller at that point, we feel like this would  
8 help.

9 And of course, you're all aware that you  
10 do need to get your pH of your water around six for  
11 your chlorine to be most efficacious. And this  
12 doesn't matter -- whether it's in the chiller or your  
13 online reprocessing or your other rinsing locations  
14 that you have throughout the plants.

15 As far as post chill, there doesn't appear  
16 to be much confidence in Sanova or Inspexx in the  
17 chiller or as online reprocessing. However, Sanova in  
18 a post-chill dip tank is effective if used in  
19 combination with Sanova at the online-reprocessing  
20 location.

21 Also, the TomCO system has been used by  
22 several companies, and they think it is doing very

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 well. This involves adjusting the pH with CO2 and  
2 then monitoring the levels of chlorine. And these are  
3 the only two interventions that one comment -- one  
4 commenter said that they would support.

5 Of course, there's a lot of other  
6 chemicals on the market with those eleven that were  
7 mentioned. No single product has been determined to  
8 be highly effective. I could go back about ten years  
9 when TSP first came out, and this was several years  
10 before online reprocessing came onto the scene.

11 Well, we did a long study looking at TSP,  
12 pre chill through a -- it was that outside bird  
13 washer. And when you looked at birds post chill, we  
14 couldn't find any effect on bacterial levels,  
15 *Salmonella* incidence, or shelf life.

16 So the majority of chillers are treated  
17 with chlorine, and they do work best when the pH is  
18 optimized. One thing that we do need to do is  
19 automate the chlorine concentration and the pH control  
20 to minimize the human elements.

21 There is an increasing incidence of  
22 brushes such as TomCO is using. There is a gain in

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 popularity of use of post-chill dips. However, there  
2 are several things that people have used as post chill  
3 that you got to be careful about your organoleptic  
4 quality of your product.

5 If you're going to a chill-pack product  
6 that's going straight to a consumer, you want to be  
7 careful about any discoloration or changes in flavor  
8 that might happen. If you're -- a part of the process  
9 is just deboning it, then you might not be quite so  
10 concerned about it.

11 But we don't have any intervention that  
12 really gets us to where we want to be by itself, so  
13 we're back to the multiple hurdle. Thank you.

14 (Applause.)

15 DR. ENGELJOHN: Well, thank you, John,  
16 very much for stepping in and making that presentation  
17 with a summary of what you found within your industry.

18 Our final presentation this morning from  
19 the industry perspective is from Dr. Randy Huffman.  
20 He's the vice president of scientific affairs for the  
21 American Meat Institute Foundation. Randy has had  
22 extensive experience with the field, particularly in

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 beef industry.

2 He comes to us with degrees in animal  
3 science from Auburn, a master's in animal science from  
4 University of Florida, and a Ph.D. in meat science  
5 from the University of Florida. And Randy's going to  
6 talk to us about the success of the beef program with  
7 regards to *E. coli*.

8 Thank you.

9 DR. HUFFMAN: Thank you very much, Dan,  
10 and thank you for the invitation to share with you  
11 today some comments regarding a different specie and a  
12 different pathogen than you've been talking about for  
13 the last day or so.

14 I am very pleased to be here. And Dr.  
15 Engeljohn at FSIS has felt that this topic would be a  
16 useful example of how a separate segment of the  
17 regulated industry is dealing with control of the  
18 food-borne pathogen in a raw product.

19 Certainly everyone in this room would  
20 recognize that there are very important differences  
21 between poultry and beef. Obviously the livestock  
22 themselves, the processing systems, the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 microbiological differences are all very important  
2 differences. And also, the interventions that are  
3 used to increase the margin of safety are certainly  
4 different.

5 But my desire today is to provide you with  
6 insight from the beef industry's experience that may  
7 assist the poultry industry and FSIS as we discuss the  
8 issue of controlling *Salmonella* in poultry.

9 As Dan mentioned, I'm with the American  
10 Meat Institute Foundation, which is the research,  
11 education and information arm of the American Meat  
12 Institute. And we represent the interests of  
13 processors and packers in the U.S.

14 Since the early 1990s, the beef industry  
15 has invested significant resources to reduce the  
16 occurrence of *E. coli* 0157 in raw beef products.  
17 Technologies such as thermal pasteurization of  
18 carcasses, steam vacuum, the use of organic acids,  
19 routine testing at various points in the process, and  
20 the implementation of good management practices have  
21 all been proven to reduce the prevalence of this  
22 organism in raw beef products.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           The limited time today and probably the  
2 interest of this group -- I won't go into great detail  
3 on all of those interventions. I really want to try  
4 to address these three main points.

5           First, it's our belief that the zero-  
6 tolerance policy implemented for *E. coli* 0157  
7 initially created a disincentive for industry and  
8 stymied progress on beef safety. I will point out  
9 when I refer to zero tolerance throughout this talk, I  
10 am talking about the adulteration policy for 0157 on  
11 beef and not necessarily the zero tolerance for fecal  
12 contamination on beef.

13           Second, a variety of industry initiatives  
14 which were bolstered by a spirit of cooperation and  
15 information sharing in a noncompetitive fashion were  
16 instrumental in creating improvements in beef safety.

17           And my third point will be that regulatory  
18 initiatives that moved beyond the reliance on the  
19 zero-tolerance framework and allowed industry to adapt  
20 and improve are very important.

21           I think it's important for us to have a  
22 brief history of this issue and a background. One of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 the -- well, *E. coli* 0157 was first isolated in 1975,  
2 and the symptoms of that disease were described in  
3 about 1982. Everything changed, as many of you know,  
4 in 1993.

5 In the Pacific Northwest, there was a  
6 major outbreak of *E. coli* 0157 illness linked to  
7 undercooked ground beef. And that triggered a major  
8 public health concern and an outcry for a significant  
9 government response to this problem. It certainly  
10 changed a lot for our industry, as well for FSIS.

11 One of the initial responses from FSIS was  
12 to strictly enforce the policy of zero tolerance for  
13 fecal contamination on beef carcasses.

14 However, by 1994, after a second *E. coli*  
15 0157 outbreak was linked to undercooked ground beef,  
16 the FSIS had announced an unprecedented new policy  
17 when then administrator of FSIS Mike Taylor announced  
18 somewhat unexpectedly at the AMI convention in 1994  
19 that *E. coli* 0157 would be declared an adulterant on  
20 raw ground beef and that FSIS would begin an end-of-  
21 the-line pathogen-testing approach to enforce this  
22 policy.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           Testing products for safety. That was the  
2 mantra among industry critics at the time and some in  
3 government. The initial reaction by industry to this  
4 newly announced policy was predictable negative,  
5 primarily because of the significant data gaps and  
6 uncertainly that this new business paradigm created.

7           Businesses that thrive do so because they  
8 sell safe food, and they do so because they have good  
9 information and are able to appropriately manage  
10 business risks. Whether those risks are financial,  
11 market risk, or in this case food-safety risk,  
12 information is important.

13           And in this case, the understanding of the  
14 risk of *E. coli* 0157 in ground beef in 1994 just -- we  
15 just didn't have good information. There was a dearth  
16 of scientific data. And there was very little known  
17 about its prevalence, about the sources, about the  
18 shedding patterns, the seasonality, the transmission,  
19 and all the other relevant scientific facts that today  
20 we somewhat take for granted. We've learned a lot in  
21 the last 12 to 15 years.

22           In light of these major data gaps in 1994,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 it would be entirely predictable and expected that  
2 businesses faced with this type of uncertainty would  
3 want to collect more data. Unfortunately, this  
4 onerous regulatory policy of zero tolerance for a  
5 pathogen in raw products punished a business for  
6 collecting the data that they so badly needed to  
7 collect. And that just -- that environment didn't  
8 create a very constructive environment for change.

9 In that 1994 speech by then administrator  
10 Taylor, he included the following remarks, and I'd  
11 like to quote. "In the case of 0157 in raw ground  
12 beef, the only satisfactory public-health goal is to  
13 eliminate contamination."

14 We must look for ways to reduce the  
15 likelihood that contaminated animals will enter the  
16 stream of commerce, reduce the risk that any  
17 pathogenic bacteria present in the intestinal tract  
18 will contaminate meat during the slaughter process,  
19 and reduce the potential for subsequent growth of any  
20 organism that may be present.

21 In short, technological innovation in  
22 production, slaughter, and processing must be

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1       harnessed and applied aggressively if we are to move  
2       effectively toward our public-health goal.     Close  
3       quote.

4                 These concepts were very appropriate then.

5       I would believe that they're very valid today.  
6       However, when these concepts were coupled with an  
7       unachievable regulatory performance standard and a  
8       lack of knowledge about this organism at the time,  
9       very little progress toward the goals articulated in  
10      that speech were made immediately.

11                So I guess I pose the question that's at  
12      the bottom of this slide.    Did the regulatory focus  
13      initially on zero tolerance for 0157 in raw ground  
14      beef result in a -- at least an initial lack of  
15      progress?

16                The scientific community at the time  
17      certainly had an opinion about this, and I'd like to  
18      quote from two different sources, first the  
19      International Commission on Microbiological  
20      Specifications for Food in their book 7, 2002.

21                And I quote.    "No feasible sampling plan  
22      can ensure complete absence of a pathogen.    It cannot

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 be guaranteed that the lot is completely free of the  
2 organism no matter how large the number of sample  
3 units."

4 A second group, Blue Ribbon Task Force,  
5 organized by the American Meat Science Association in  
6 1999, published a document called The Role of  
7 Microbiological Testing in Beef Food Safety Programs,  
8 The Scientific Perspective.

9 One of the conclusions that is in that  
10 document is the following. Declaration of a food-  
11 borne pathogen as an adulterant in raw products,  
12 first, discourages testing for that pathogen, second,  
13 leads to a false sense of security among consumers,  
14 third, discourages the evaluation of control measures,  
15 and finally, encourages the inappropriate use of  
16 microbiological control measures.

17 So that was the opinion, at least at the  
18 time, of the scientific community on this particular  
19 topic.

20 So to summarize the first point, I think  
21 the zero-tolerance policy did have some negative  
22 impact, at least initially, on the collection of data

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 and movement toward the goal.

2 But during that period from '94 to 2000,  
3 one thing that FSIS did provide was routine testing  
4 data and establishment of prevalence of the organism  
5 on raw ground beef. It was initially assumed to be  
6 very low. And as methods for sampling and testing  
7 improved, that prevalence estimate was increased to  
8 around 1 percent. And that's based on about 5 to  
9 6,000 samples analyzed annually by FSIS.

10 Early focus of control was on the carcass  
11 surface, and industry was compelled to comply with the  
12 fecal zero-tolerance regulation, testing for generic  
13 *E. coli* as an indicator of process control and seeking  
14 and validating various carcass interventions.

15 However, by 1999, during an FSIS public  
16 meeting much like this one today -- and this was on  
17 0157 -- the Centers for Disease Control shared data  
18 that the public-health burden was not improving for  
19 illnesses associated with *E. coli* 0157. And FSIS  
20 shared data that indicated a rising trend in the  
21 prevalence of the pathogen on raw products. This is  
22 in 1999.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           At about this time, industry had also been  
2 made aware of data showing that the prevalence of 0157  
3 on livestock arriving at the meat plant were much  
4 higher than previously thought and that the primary  
5 source of *E. coli* 0157 transfer was not the fecal-  
6 ingestor route. However, it was determined to be  
7 primarily from the hide. And that was certainly a new  
8 finding with data collected during this time frame.

9           What was occurring really at this point in  
10 time was an evaluation in the understanding of this  
11 pathogen and its transference to beef. And the data  
12 was beginning to become available to make valid  
13 assumptions about how to use the data and to control  
14 the organism.

15           The rate of understanding and adoption of  
16 new technology rapidly increased during this time  
17 frame. One significant driver of change was when the  
18 AMI board of directors voted unanimously to consider  
19 food safety as a noncompetitive issue within the  
20 industry.

21           This led to a lot of data sharing and  
22 cooperating among companies that -- and it looks like

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 I'm seeing a lot of that within the industry  
2 represented here today as well, and that's great.

3 The other thing that occurred during this  
4 time frame was significant investment in beef-safety  
5 research. Two groups that invested significant  
6 dollars in this area were the AMI Foundation as well  
7 as the National Cattlemens Beef Association. These  
8 efforts were focused primarily on the post-harvest  
9 controls initially, and then also work has been done  
10 in the pre-harvest area, which I'll talk about a  
11 little more in a minute.

12 Beef-industry customers certainly played a  
13 role by working cooperatively with suppliers on  
14 auditing and sampling programs that enhanced our  
15 knowledge about 0157.

16 One very significant driver of change has  
17 been the implementation by industry of expanded and  
18 robust *E. coli* 0157 trim-sampling and testing programs  
19 based upon ICMSF sampling and testing guidelines that  
20 provide establishments with a reasonable confidence  
21 that the organism will be found in a given lot if it  
22 is present.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1                   FSIS has now adopted a version of this  
2 industry-initiated approach to sampling for -- in the  
3 current raw-ground-beef products baseline survey.

4                   Better data about processes will lead to  
5 more effective control measures, and these data can be  
6 used to verify that best practices are working.

7                   Implementing processes and system changes  
8 is never an easy or inexpensive task, as Bruce has  
9 just pointed out. And these issues present a major  
10 challenge. Development and implementation of best  
11 practices by industry and the joint sharing of this  
12 information across all segments of the chain was  
13 accomplished in a variety of ways.

14                   One of the those ways has been the  
15 organization of the Beef Industry Food Safety Council,  
16 which is managed by the NCBA, the National Cattlemens  
17 Beef Association. And this is a coordinated effort of  
18 producers, processors, retailers, and food-service  
19 operators.

20                   And these -- this group has collectively  
21 developed guidelines for industry best practices for  
22 every critical step in the beef-processing chain.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 I've listed the current documents that are available  
2 on the BIFSCO website. These are dynamic documents  
3 that are updated on an annual basis or, as needed,  
4 more frequently.

5 We also meet at least once per year at the  
6 Beef Safety Summit in the spring and on an ad-hoc  
7 basis as needed.

8 Another way that best practices have been  
9 shared is through workshops by various trade  
10 organizations. One example is the AMI Foundation's  
11 workshop for sharing of best practices on slaughter  
12 practices. This was held in 2003 in Kansas City.  
13 Certainly for those of you that were there, there was  
14 an excellent time for sharing of information.

15 The other area that I wanted to talk about  
16 was the pre-harvest work. And quite a bit of research  
17 has been funded in finding and looking for  
18 interventions on pre harvest. However, there -- to  
19 date very few that have been proven effective in large  
20 field trials. And certainly this is an area that we  
21 continue to focus on.

22 My third point today is really the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 relationship of FSIS policy to -- toward improvements.

2 And their policy certainly has evolved since 1994.

3 And while zero tolerance still exists, there are new  
4 directives that are more reasonable.

5 And these initiatives have continued to  
6 keep significant focus and pressure on beef-processing  
7 establishments. In-depth food-safety assessments have  
8 identified weaknesses in HACCP plans and have led to  
9 needed adjustments in HACCP plans.

10 One example is the identification of the  
11 need to consider the risk of trim harvested on the  
12 slaughter floor prior to the complete set of carcass  
13 interventions. Things such as this have been  
14 identified through this process. The in-depth FSAs  
15 serve as a constant pressure point for industry to  
16 improve.

17 Challenges exist as industry and FSIS  
18 evaluate data though. This is a really important  
19 factor. One of the steps that FSIS has taken is that  
20 when testing for *E. coli* 0157, FSIS now acknowledges  
21 that under certain circumstances, negative testing  
22 results can be used to discern acceptable product from

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 unacceptable product.

2 As a result of a recent directive, when  
3 the pathogen is found in a test sample, only product  
4 predetermined to be represented by the sample is  
5 deemed unacceptable or adulterated. This  
6 implementation of policy, while still burdensome,  
7 allows businesses to collect the data that they need  
8 and to manage the risk.

9 However, I would ask how should FSIS and  
10 industry react when a single positive 0157 result  
11 occurs that from a statistical process-control  
12 perspective is simply the result of common-cause  
13 variation, for which there is not meaningful  
14 corrective action.

15 When data indicates a process is in  
16 control, yet low-level positives exist, AMI continues  
17 to advocate to FSIS that they must adopt process-  
18 control-based reactions to positive test results  
19 rather than requiring meaningless HACCP reassessments  
20 and unproductive efforts aimed at corrective actions.

21 Industry and FSIS must be more in tune  
22 with generally recognized scientific principles for

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 statistical process control and the realization that a  
2 certain low level of positives in raw product will  
3 continue to occur.

4 I want to conclude with some data to just  
5 show improvement that has been made. And this is from  
6 routine FSIS sampling of ground beef. It represents  
7 about 5 to 6,000 samples a year, I believe. And there  
8 has been a continuing decline since 2000.

9 I show the data only since 2000, since  
10 that's the point in time when the sampling and testing  
11 methods have been consistent. And it also shows the  
12 point in time where we had the peak and prevalence of  
13 about .8 percent. It looks like this decline is  
14 sustained at this point, and we certainly hope that  
15 we'll stay that way.

16 Combined with that, we've seen a decline  
17 in recalls. Certainly this is an important factor.  
18 It's driven by a variety of things such as hold and  
19 test programs. But certainly we've seen a reduction  
20 in the number of announced recalls each year, and  
21 that's a great thing. None so far in 2006.

22 But I would say that the most important

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 data is from Centers for Disease Control and their  
2 FoodNet Data set. And this data shows that since the  
3 establishment of FoodNet and the tracking of illnesses  
4 related to 0157, that we've seen a steady decline --  
5 an important decline. In fact, CDC reports that  
6 there's actually a 42 percent decline over the  
7 baseline years of '96 to, I believe, '98.

8 The efforts have led to the achievement of  
9 the healthy people 2010 public-health goal of one  
10 illness per hundred thousand population. And we've  
11 achieved that goal five years ahead of schedule. So  
12 that's certainly something that government and  
13 industry should be proud of.

14 So I'd like to close today with some  
15 questions for you to consider. I certainly have my  
16 opinions about the answers to these questions, but I'd  
17 strongly encourage each of you to formulate your own  
18 honest answers to these.

19 First, is the *E. coli* 0157 problem in beef  
20 solved? Second, have improvements in the safety of  
21 beef been made in the last decade? Certainly I hope  
22 the data I showed would say -- would tell you yes.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           Has zero tolerance for 0157 caused change  
2 in the beef-processing industry? Well, certainly it  
3 caused change. There's no denying that. The question  
4 is was that the best policy at the time.

5           Have the changes led to reduction in human  
6 0157 illnesses related to beef consumption? The CDC  
7 data that I just showed would indicate that the answer  
8 to that possibly is yes, although I would encourage  
9 our public-health officials to improve our ability to  
10 track and attribute foods -- specific foods to  
11 illness.

12           That certainly is an area that is lacking  
13 today. The data that CDC collects is for all food  
14 sources, not any one particular one in the FoodNet  
15 data.

16           And finally, the question has zero  
17 tolerance for 0157 been good public policy? That's  
18 certainly a debatable question, and we'd all have our  
19 own opinions. I would encourage both FSIS and the  
20 economic research service to take a retrospective look  
21 at this policy now after a number of years and to  
22 consider both the cost and the benefits.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           We have a lot of new data now on  
2 prevalence on illnesses, and certainly we can generate  
3 a lot of data on the cost, because this policy has  
4 been a rather expensive one. I think it would be a  
5 good exercise to evaluate the policy at this point in  
6 time.

7           So to summarize -- and I'll try to maybe  
8 reiterate my three main points in a slightly different  
9 way. First, achieving enhanced meat safety should  
10 begin with a rational and achievable regulatory policy  
11 that is based upon a necessary public-health goal that  
12 is measurable.

13           Second, collect data to fully understand  
14 the process and use the data to develop valid control  
15 strategies and best practices. And finally, industry  
16 must share the knowledge and best practices in a  
17 noncompetitive fashion.

18           I sincerely appreciate the attention today  
19 and will close by saying that the industry's food-  
20 safety record is good and getting better. And as I  
21 think several speakers have already said, there are no  
22 silver bullets. It takes dedication and hard work and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 continued effort. Thank you very much.

2 (Applause.)

3 DR. ENGELJOHN: Well, thank you.

4 I think if we could we'll go ahead and ask  
5 the panelists to remain up here, and we'll take  
6 questions now and then move into a break after that.  
7 So we'll see how this goes.

8 But as we did yesterday, if you would move  
9 to the central microphone in the room, announce who  
10 you are and who you represent, and then ask your  
11 question, and we'll try to get you an answer.

12 And perhaps if we could just turn the  
13 lights on. Somebody else get up to the microphone,  
14 and we'll figure out the lights.

15 Are there any questions on the phone,  
16 since we have none hear in the room?

17 MS. PETERSON: Hi. My name is Robin  
18 Peterson. I'm with PURAC. And I have a general  
19 question to the members of industry. I'm wondering,  
20 in terms of the incidence and the prevalence of  
21 *Salmonella* coming in on live birds -- that's  
22 obviously -- this -- as I understand it, been

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 increasing. And this may relate to the pre harvest.

2 But I'm wondering what the effect of  
3 reduction of antibiotic use is playing in that, as  
4 well as numbers of birds in houses. And I'm assuming  
5 that companies are looking at the live end as well as  
6 the back end. And again, this may have been a more  
7 appropriate question for the last public session that  
8 you held. I'm just wondering if there's any comments.

9 DR. ENGELJOHN: Any of you want to take  
10 it? Just --

11 DR. ROOP: Yes. Thank you. Richard Roop,  
12 Tyson Foods. Actually, I was asked that question  
13 yesterday about the effect of reduction -- use of non-  
14 therapeutic antibiotics and its relation to reduction  
15 in -- in crease in *Salmonella* incidence.

16 That's certainly been a factor that's been  
17 discussed among the industry technical folks.  
18 However, there have been no conclusive studies to say  
19 that for sure. As I mentioned to an individual  
20 yesterday, I think that would be an excellent Ph.D.  
21 thesis for that to be determined.

22 DR. STEWART-BROWN: One comment. If --

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 it's absolutely irrefutable in my mind that if gut  
2 health is influenced negatively, *Salmonella* carriage  
3 goes up. Those two go together almost every time  
4 we've looked at it that way.

5 If you don't take care of gut health when  
6 it goes bad, you're not -- that's a detrimental  
7 approach to food safety overall. So the -- if you say  
8 whether the reduction of antibiotics in the feed --  
9 and then that has resulted in more variability in gut  
10 health. I think that's a very valid question and an  
11 appropriate question.

12 If you said does the presence of  
13 antibiotic in a healthy gut negatively or positively  
14 influence *Salmonella* carriage, that's quite another  
15 question. But the biggest piece as far as I'm  
16 concerned is that if you have a gut-health issue, you  
17 need to get it right. And -- because it's a  
18 detrimental component to your *Salmonella* carriage.

19 DR. ENGELJOHN: Any other questions in the  
20 room?

21 DR. O'CONNOR: I actually have --

22 DR. ENGELJOHN: Yes.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 DR. O'CONNOR: It's more of a comment or a  
2 question to your question, which is -- I think you  
3 prefaced your question with almost stating a fact  
4 which I'm not sure is a fact, that the level of  
5 *Salmonella* coming into the plant has increased. Is  
6 that the case is my question.

7 MS. PETERSON: You would know better than  
8 I.

9 DR. O'CONNOR: I think that's a very good  
10 question, and it's actually one that we've tried to  
11 look at within this group from an industry standpoint.

12 Because I think one of my questions has always been  
13 what's the most appropriate way to measure your  
14 *Salmonella* load coming into the plant.

15 So for instance, I do a lot of drag swabs  
16 in broiler houses. But I know other people sitting  
17 here -- they'll do ceca pouches, you know, and they'll  
18 collect, you know, six from six birds in a house. And  
19 are those persons -- are their results really  
20 comparable, you know, to mine?

21 If I had to look at data from 2001 when I  
22 first started drag-swabbing houses to 2006, I'm not

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 really sure that I can say that -- well, I certainly  
2 can't say the load has increased, because I don't do  
3 enumeration of *Salmonella*.

4 But in terms of the incidence, presence or  
5 absence, what I see is kind of a normal distribution  
6 curve. You know, I have some farms that just don't  
7 show up positive. I have some that oftentimes show up  
8 positive. And then I have a very kind of middle  
9 average group that sometimes are positive and  
10 sometimes are not.

11 So I still question even my own monitoring  
12 on the live side in terms of the significance of that  
13 information. I think it's a good question. I just  
14 don't know if I, from my own data, see an actual  
15 increase coming in from the field.

16 DR. ENGELJOHN: Question, Felicia?

17 MS. NESTOR: I'm Felicia Nestor with Food  
18 and Water Watch, and I have a question for Dr.  
19 Huffman. On the slides, you were talking about -- and  
20 I don't know where you're sitting right now. Okay.  
21 You were talking about the continuous decline in  
22 recalls and findings of *Salmonella* -- I'm sorry; *E.*

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1     *coli*.

2                   And there was a real extreme drop between  
3     2002 and 2003.  And in the consumer community -- and  
4     we've -- you know, we take a look at that, and we say,  
5     What happened there, because, whatever happened there,  
6     we like it.

7                   And one of the things that happened in  
8     2002 was the ConAgra recall.  And at that point,  
9     immediately, FSIS announced that no large plants -- no  
10    plants would be exempt from FSIS testing.  Prior to  
11    that, if you had a -- if you performed a certain  
12    number of processes or certain particular processes,  
13    you wouldn't get FSIS testing.  So all of a sudden, no  
14    plant would be exempt from FSIS testing.

15                   And secondly, the Agency said it was going  
16    to keep a database of suppliers so that when FSIS  
17    found *E. coli* further along the distribution chain,  
18    like at the smaller plants or the smaller grinders of  
19    retail, that it would keep a database of the  
20    slaughterhouses.

21                   So I mean to us, that looks like it was  
22    accountability.  All of a sudden, accountability was

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 forced into the system, and the producers of trim and  
2 the producers of course-ground product no longer could  
3 sort of fly under the radar screen.

4 And if I'm not mistaken, Bill Smith said  
5 that after they implemented that, that's when test and  
6 hold went up really a lot in the large plants. And if  
7 I'm not mistaken, you know, that's when inspectors  
8 told me all of a sudden, you know, chili became a  
9 favorite. And we've got a lot of lots of contaminated  
10 *E. coli* product now going to chili factories as  
11 opposed to, you know, out into the market in raw form.

12 So we talk about this in the consumer  
13 groups. We want to know what -- how do you respond to  
14 the idea that it could have been that accountability?

15 That's relevant to one of the changes that FSIS is  
16 proposing in the new Fed Register notice, which I  
17 think we're going to discuss later.

18 DR. HUFFMAN: First of all, that graph --  
19 and it's not up on the screen. But it's important to  
20 recognize -- you characterize that drop as -- I'm not  
21 sure of the word you used, but significant. Certainly  
22 there's an important decline, but it's important to

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 recognize that those bars represented percentages that  
2 were all under .8 percent.

3 So the decline -- I haven't done any  
4 statistics on those data, and I'm not sure it would be  
5 appropriate, since they are routine regulatory  
6 samples. But it was a modest drop, if you will, in  
7 terms of true numbers, because the rate of positives  
8 is less than .8 at the peak.

9 So with that as a basis for our  
10 discussion, I appreciate your question. One of the  
11 points that I did make in the talk was the recognition  
12 of a regulatory policy that allows for a company to  
13 define the lot that is represented by a sample and the  
14 recognition that a negative result would allow that  
15 product to be considered safe for distribution.

16 That particular change did allow for a  
17 significant increase in testing and data collection.

18 MS. NESTOR: So you're saying that the  
19 industry itself then started testing more, and up  
20 until that point, they wouldn't do the testing.

21 DR. HUFFMAN: Certainly there was an  
22 increase in the amount of industry testing over this

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 time frame that I described in the talk. Yes.

2 MS. NESTOR: So -- and can you tell me the  
3 years on that again? You're -- so you don't think  
4 that industry testing really went up in 2002.

5 DR. HUFFMAN: I think that it probably  
6 did, yes, as a result of that policy.

7 MS. NESTOR: Okay. I know you're saying  
8 that the numbers didn't go down that much in terms of  
9 like absolute numbers. But if you look at the CDC  
10 data as well on a month-by-month -- if you chart it  
11 month by month, there's a real good drop in 2002 as  
12 soon as these new policies were adopted, and that  
13 number hasn't gone up since then.

14 DR. HUFFMAN: Well, I guess I would say  
15 that testing is certainly one component of the total  
16 system that is addressing pathogen. And one of the  
17 points I wanted to convey in that talk is that  
18 collection of data is the key component of assessing  
19 the effectiveness of the entire food-safety system and  
20 all the interventions that have been put in place.

21 And by the collection of that data and the  
22 evaluation of those systems, I don't think you can

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 state that any one particular intervention has any  
2 greater impact. It's a total-systems approach.

3 MS. NESTOR: One of the other reasons I'm  
4 focusing on the accountability is because if you look  
5 at the OIG ConAgra report, it shows that in the months  
6 prior to that recall, ConAgra had found *E. coli* in  
7 trim, you know, 46 out of -- I can't remember how many  
8 days.

9 And the OIG found that ConAgra did not do  
10 the right thing about that. So, you know, ConAgra was  
11 testing. ConAgra knew. But it wasn't until the  
12 accountability was forced into the system that the  
13 numbers go down.

14 I don't know. Maybe it's not correlated.

15 It looks to us like it's correlated and --

16 DR. HUFFMAN: Okay. I just -- say I'm not  
17 necessarily disagreeing with you that there was a  
18 decline over that time period. And I don't want to  
19 comment on the OIG report, so --

20 DR. MASTERS: I guess -- this is Barb  
21 Masters. And I would just comment -- and I think it's  
22 consistent with what Dr. Huffman is saying. I think

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 that's the point at which we asked the industry to  
2 reassess their HACCP programs.

3           And they looked at the design of their  
4 HACCP programs, and they significantly redesigned  
5 their programs. And it's the entire redesign of their  
6 programs, and it's the total package of the  
7 interventions they put in place as well as the testing  
8 that they put in place to verify the changes they put  
9 in place that I think -- that you're seeing the  
10 changes.

11           It's not just the testing, but it's the  
12 interventions they put in place as well as the testing  
13 to verify the effectiveness of those interventions  
14 that I think -- you're seeing the changes, Felicia.  
15 So that's the point at which we asked them to reassess  
16 their programs, and that's where we believe you start  
17 seeing those declines.

18           So it's not just the testing, but it's the  
19 overall reassessing their programs. They had the  
20 interventions, but it's putting them into their  
21 overall food-safety programs. They're not all in  
22 their HACCP plans.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           It's prerequisite programs. It's SSOPs.  
2           It's HACCP plans and the testing they're doing to  
3           verify the effectiveness of their interventions. And  
4           so it's the overall package that I think Randy's  
5           talking about. It's the interventions and how  
6           effectively they're working. It's the total package  
7           that -- I believe you start seeing the declines.

8           DR. ENGELJOHN: Thank you.

9           Next question.

10          DR. BAILEY: Stan Bailey, Agriculture  
11          Research Service. A little bit of a comment and a  
12          question to Randy and maybe others. And it's spurred  
13          by your data that you showed, Randy. 0157 is  
14          attributable almost exclusively to beef, not totally,  
15          but primarily to beef.

16          And so as an accountability or a  
17          measurability of the results of the industry's and  
18          regulatory agencies's perspectives, it's fairly easy  
19          to see that you're getting us pretty significant  
20          reduction in 0157 coming from your beef products.

21          And CDC at the same time is showing a  
22          fairly significant reduction in human illnesses. So

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 it's at least superficially fairly easy to draw a line  
2 between the two things.

3 *Salmonella's* remained flat in the CDC  
4 data. *Salmonella* is pretty flat or actually slightly  
5 going up maybe in the poultry industry data, which is  
6 not a good thing in that that's something that most  
7 people are working toward trying to pull down. And  
8 whatever measures need to be taken need to be taken.  
9 No argument there.

10 But as those of us in government and, I  
11 suspect, in industry -- we all have milestones and  
12 guidelines we're working against to show  
13 measurability. If we reduce *Salmonella* in chicken 50  
14 percent, 75 percent, are we going to be able to have  
15 any accountability, measurability across to the human  
16 side?

17 Because *Salmonella* isn't just a poultry-  
18 industry issue. It certainly is a poultry-industry  
19 issue. But whereas 0157 is almost exclusively a beef-  
20 industry issue, *Salmonella* is spread out in a lot of  
21 different directions.

22 And the attribution data we have is not

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 particularly great, and that leaves some openness for  
2 discussion. But of the attributions that we can  
3 definitely know about, probably only -- less -- well  
4 less than 50 percent are directly related to chicken.

5 So when we look down the road and decide  
6 if our efforts are going to be effective, how are we  
7 going to measure those, I guess, is the question.

8 DR. RAYMOND: Dan, I'll take a crack at  
9 that.

10 Dr. Raymond. There's a couple things.  
11 And it's a good point. And sometimes I fail to  
12 acknowledge that when I give talks. *Salmonella* comes  
13 from a lot of sources. We know that. And thank you  
14 for bringing that back up and back on the table.

15 And it may not be the same correlation as  
16 I -- and, Randy, yesterday morning when I opened up, I  
17 used the same slides you used -- not exactly the same.  
18 You -- somebody made yours; somebody made mine. But  
19 it's the same talk that I've given many times.

20 We see a reduction in the sampling. We  
21 see a reduction in recalls. We see a reduction in  
22 human illness. That's nice because some of the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 naysayers will say, Sure, you got a decrease in  
2 sampling, because you're sampling just the first shift  
3 or whatever; you made a change in when you sampled or  
4 what you sampled, and, you know, numbers lie, and we  
5 can manipulate that stuff.

6 But when you have a recall based on  
7 investigations of outbreaks, when you have sampling in  
8 the plants and when you have human illness proved by  
9 culture and those things correlate as nicely as they  
10 do for *E. coli*, it doesn't take a rocket scientist to  
11 say they must be related.

12 *Salmonella* is down 8 percent during the  
13 same time that *E. coli* is down 42 percent -- overall  
14 for *Salmonella*. If you look at *Salmonella*  
15 Typhimurium, it's down about 42 percent, just about  
16 like *E. coli*. But if you look at some of the other  
17 serotypes, they're going up.

18 And some of the *Salmonella* serotypes are  
19 related more to eggs or more to product or produce. I  
20 mean, by doing more serotyping, we can, hopefully,  
21 help answer your question to a degree. Is it coming  
22 from eggs? Is it coming from produce? Is it coming

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 from poultry?

2           It's not going to be as perfect or as  
3 easy, but we will try to do that. And we have  
4 requested extra funding to do more *Salmonella* testing  
5 and serotyping for our risk-based inspection program  
6 that we'd like to get into so we can make those  
7 correlations.

8           But we're also seeing some shifts like --  
9 Enteritidis, which used to be, Well, it must have  
10 come from the eggs. But now we're seeing it coming  
11 from the carcasses. And *Salmonella's* a strange bug  
12 that way, it seems to me, that it can make those  
13 shifts.

14           It's becoming more heat labile. Heat is  
15 not killing it like it used to. It -- there's a lot  
16 of things going on with *Salmonella* that will -- and I  
17 mentioned yesterday public health continues to change,  
18 and we must try to keep the science going so we can  
19 change with it.

20           So again, I just thank you for bringing it  
21 on the table. I was criticized yesterday very  
22 privately for not acknowledging that. I understand.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 And -- but to the -- for the industry -- I want them  
2 to know that we do understand. I do understand that  
3 *Salmonella* -- human-borne illness can come from other  
4 resources.

5 I hope to see a reduction in the sampling  
6 product. I hope to see a reduction in human illness.

7 And we'll make kind of a vague leap of faith that  
8 that must be related. Because I can't control  
9 produce. And sometimes we can control eggs, and  
10 sometimes we can't control eggs.

11 But we can work with the poultry industry  
12 for carcasses and ground product.

13 DR. MASTERS: This is Barb Masters. And I  
14 will add to that. We are working with our public-  
15 health partners at the Centers for Disease Control,  
16 and we have put some funding towards some attribution  
17 studies. They're very acutely aware that we're  
18 interested in having attribution.

19 And the first place we've asked them to  
20 begin to work is on *Salmonella* because of the  
21 recognition that certainly while not *E. coli* 0157:H7  
22 comes from beef -- we recognize there's a little bit

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 more correlation there. And so we've asked them to  
2 begin their work on *Salmonella*.

3 So there is work going on with CDC. So  
4 that work has begun. It's not an easy project, and  
5 it's not an inexpensive project, but there is funding  
6 going towards that attribution work at CDC.

7 DR. ENGELJOHN: As the next speaker walks  
8 up to the microphone, if there is one -- and I'll just  
9 chime in as well -- this is Engeljohn from FSIS -- and  
10 just point out that the Federal Register document that  
11 we did publish wasn't specific to broilers. It was to  
12 all the classes that were all products we regulate.

13 So we recognize there's a need to look at  
14 those for which there is a special concern and then go  
15 through all the product classes. So that's our  
16 intention.

17 Did anyone else want a question here in  
18 the room? We'll ask again on the phone.

19 And while that's happening, for those of  
20 you who might be listening on the webcasting -- the  
21 netcasting or on the phone, we are directing those  
22 individuals who are watching this and listening to

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 this that you can call in. So just make sure that if  
2 you see that information on the webcast, that you  
3 do -- we'll welcome your questions.

4 Any other questions here?

5 (No response.)

6 DR. ENGELJOHN: All right. Then let's  
7 take a break.

8 (Whereupon, a short recess was taken.)

9 DR. ENGELJOHN: Welcome back, everyone.  
10 We're going to start the last portion fo the day-and-  
11 a-half session that we've had on post-harvest controls  
12 for *Salmonella*.

13 Our speaker from FSIS is a new employee to  
14 FSIS. She joined us in July 2005. Dr. Patty Bennett  
15 graduated with her doctor of veterinary medicine  
16 degree from the University of Florida and has a  
17 master's degree in biology.

18 We welcome her. She's one of our  
19 technical analysis staff officers. And she's going to  
20 talk to you about the FSIS policies on *Salmonella* that  
21 we published this last Tuesday on our webpage. And  
22 that will be officially published in the Federal

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Register this coming Monday.

2 Dr. Bennett.

3 DR. BENNETT: Thank you, Dan.

4 As -- since Dr. Bailey, as he walked back  
5 to his seat, walked past me just to harass me, it  
6 reminded me that I'd like to thank all of the  
7 presenters these past couple of days. You've actually  
8 been very wonderful. You were very gracious while  
9 Laura and Bill and I were harassing and haranguing and  
10 intimidating you to turn in your information.

11 And I do like to thank you, because again,  
12 you all did a wonderful job. And you were very good  
13 about stepping up to the plate, especially Dr. Rice,  
14 who showed up today to give Dr. Krushinski's  
15 presentation.

16 So what I would like to talk about today  
17 is -- are the policy initiatives that have been put  
18 forth in the Federal Register notice that, like Dan  
19 said, will be officially posted this coming Monday.  
20 However, for those individuals who are interested in  
21 reading it now, it is actually posted on the Agency  
22 website and has been so since this past Tuesday.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           And what these initiatives will do is to  
2 explain the changes that FSIS is going to take  
3 regarding reporting and using the results from his  
4 *Salmonella* verification sampling program.

5           The purpose of the policies are basically  
6 to enable the Agency to better assess the process  
7 control for pathogens in all classes of raw products.  
8       FSIS is especially interested though in assisting the  
9 broiler industry in reversing the upward trend of  
10 high-positive *Salmonella* sample sets.

11           And as -- it's been mentioned before, but  
12 I will say it again. Since 2003, the poultry classes,  
13 particularly broilers, have experienced an upward  
14 trend, which is actually above what they had  
15 previously obtained at lower levels.

16           There are eleven actions that have been  
17 put forth in the federal notice, and I will make  
18 mention of each one very briefly. And I will do so in  
19 the order that they have been presented in the Federal  
20 Register notice.

21           So action 1. The results of individual  
22 sample tests will be sent to establishments as soon as

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 those results have been made available. That means  
2 that FSIS intends that establishments take this  
3 information and adjust their process controls as  
4 needed.

5 Action 2. FSIS will post quarterly,  
6 rather than annually, the nationwide *Salmonella* data  
7 by product class.

8 Action 3. FSIS will begin collecting swab  
9 samples from turkey carcasses. Now, in this way the  
10 Agency will be able to assess the process control for  
11 this class according to the baseline performance  
12 levels, which right now are at 19.6 percent.

13 What the Agency is also hoping is that by  
14 working with the turkey-carcass class and helping them  
15 with their process control, that this will also help  
16 the ground-turkey class and their process control.  
17 Right now they have the -- actually the highest  
18 performance standard of all of the classes for raw  
19 products, and that's at 49.9 percent.

20 And again, if the source material are  
21 turkey carcasses, then by again making sure that the  
22 turkey-carcass class has improved carcass control,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 then it should trickle down, and we should see a  
2 positive effect with the ground-turkey class.

3 Action 4. To better allocate Agency  
4 resources, FSIS is going to characterize  
5 establishments by their performance within three  
6 categories. And again, this has been mentioned  
7 before, so this is isn't new, but I'll go ahead and  
8 repeat the categories just so you don't forget.

9 So category 1. In category 1 -- this is  
10 best pathogen control. Establishments are producing  
11 products that have very low exposure of the public to  
12 *Salmonella*. With category 2, we have more  
13 intermediate pathogen control. Again, these  
14 establishments are producing products with elevated  
15 exposure of the public to *Salmonella*.

16 And then with category 3, this is where we  
17 find the least pathogen control. Again,  
18 establishments are producing products with the  
19 greatest exposure of the public to *Salmonella*.

20 Action 5. Now, based on those categories,  
21 scheduling frequencies will be modified. Therefore,  
22 for those establishments that are actually showing

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 poor performance, poor process control -- they may be  
2 scheduled much more frequently with multiple sets in a  
3 year's time.

4           Whereas for establishments that are  
5 showing good control -- they may be scheduled as  
6 infrequently as once every two years.

7           Action 6. FSIS will conduct food-safety  
8 assessments in those establishments that, again, are  
9 showing poor performance. And we want to do this  
10 before they actually have a failed set. And in  
11 addition, the Agency wants to focus on those sample  
12 sets that contain serotypes that are known to cause  
13 human illness.

14           And we also know that when there is  
15 increased agency scrutiny in terms of food-safety  
16 assessments, we find that plants tend to have improved  
17 performance regarding control of *Salmonella*. Fancy  
18 that, but that's what we found.

19           Action 7. FSIS will issue compliance  
20 guidelines regarding *Salmonella* during slaughter of  
21 broilers. Now, Dr. Engeljohn just asked me two  
22 minutes before I made this presentation where the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 compliance guidelines are.

2 And since I'm one of the writers, I will  
3 tell you right now, please don't expect them this  
4 afternoon. Don't expect them Monday either. But I do  
5 promise that when I return to D.C., this will be the  
6 first thing that I work on.

7 Action 8. FSIS will more quickly  
8 determine serotypes for the sample sets.

9 Action 9. FSIS will pursue policies on  
10 subtyping or fingerprinting *Salmonella* utilizing or  
11 using pulsed-field gel electrophoresis. FSIS is part  
12 of Pulsenet, which is a national network coordinated  
13 by the CDC. Other members include the FDA, state  
14 health departments -- as well as local health  
15 departments.

16 Some of the objectives of this network is  
17 to provide real-time communication among partners, as  
18 well as to facilitate early identification of common-  
19 source outbreaks.

20 Action 10. In order to ascertain that we  
21 are indeed seeing pathogen reduction in organisms like  
22 *Salmonella* and *Campylobacter*, FSIS will conduct

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 ongoing baseline studies in all classes of raw  
2 products. And in addition to determining whether or  
3 not yes, we've got it; no, we don't, the Agency will  
4 also be looking at what kind of changes in serotypes  
5 are we seeing, as well as patterns of antibiotic  
6 resistance.

7 And action 11, the final one. Again, the  
8 Agency will be watching these categories that are in 2  
9 and 3 and showing less process -- good process  
10 control -- and that they are adequately moving into  
11 category 1, which is best pathogen control.

12 Now, the first focus of the Agency will be  
13 on the control of *Salmonella* in slaughter  
14 establishments. But that doesn't mean that the Agency  
15 is disinterested in the ground-product classes. But  
16 we do realize that you first need to control what's  
17 going on with the source materials before you're going  
18 to control what's going on with the ground-product  
19 classes.

20 FSIS is very interested in improving the  
21 process control regarding *Salmonella* in all classes of  
22 raw products. To that end, they Agency is considering

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 increased steps to improve control of levels of  
2 *Salmonella*.

3 Now, what you see on this slide are  
4 incentives that the industry is considering. So with  
5 establishments that are showing poor performance, poor  
6 process control, the Agency is considering publishing  
7 the names of those establishments as well as their  
8 performance status on the Agency website.

9 For those establishments that are showing  
10 good process control, the Agency is considering  
11 allowing increased slaughter volume.

12 Now, these actions will go into effect  
13 immediately, but that doesn't mean that we are not  
14 encouraging people to make comments on what we have  
15 put out. And there will be an open-comment period for  
16 individual stakeholders to provide input to FSIS  
17 regarding this notice.

18 And in fact, we are very much hoping that  
19 people will participate and that you will give us your  
20 feedback and your suggestions so that we can make this  
21 as good as it can be. And I think that's it.

22 (Applause.)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 DR. ENGELJOHN: Well, with that, run  
2 through the options contained within the Federal  
3 Register document. At this time, we are open to any  
4 questions that the attendees here may have, as well as  
5 those on the phone, that we can clarify or give  
6 additional information about.

7 Yes.

8 DR. BAILEY: Stan Bailey, Agriculture  
9 Research Service. Dr. Bennett, just for some  
10 clarification for me and I suspect others, you talk  
11 about the different classes. And I don't remember the  
12 numbers from Sean's presentation, but say the lower --  
13 class 1, the lower 25 percent.

14 If that number is six -- then you bring in  
15 the different serotypes and different considerations  
16 there. If you -- if that number 6, whatever it is --  
17 I don't remember what it is, but if that number's 6,  
18 and you have five Kentuckys which are not a human and  
19 one Enteritidis or Heidelberg or something else, does  
20 that put you in category 2, or are you in category 1  
21 because the majority of them are Kentuckys?

22 DR. ENGELJOHN: I'll take that question

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 and give you a response. And again, this is the type  
2 of information that we would encourage you to write in  
3 terms of your comments to the document, so we can make  
4 sure we get them on the record and that we do have a  
5 process in place to actually address the issues.

6 But from the perspective of the Agency,  
7 process control is the issue. And there are  
8 limitations to the data that we do collect. We  
9 collect one rinse sample per bird per day.

10 There are issues about whether or not  
11 we're actually identifying all the types of *Salmonella*  
12 that may be present within that rinse sample, because  
13 we know that our policy and our procedures that we  
14 have posted on the webpage actually do have us  
15 selecting the most dominant colony that we find. And  
16 so there may in fact be other types of *Salmonella*  
17 present. So more information about that is something  
18 that we would be looking into.

19 We look at the issue of *Salmonella* process  
20 control as an indicator of what's happening. We  
21 certainly are going to take into account the types of  
22 *Salmonella* that are present. And as you mentioned,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 Kentucky may in fact be the only one that's identified  
2 in the sample that we collect and that we've analyzed  
3 for, and that is a factor that we would take into  
4 account.

5           You should know that the Agency does have  
6 a team of technical experts that are preparing for our  
7 purposes -- of how we will guide our district managers  
8 and our inspection resources with regards to when and  
9 how we would target frequency and type of testing and  
10 activities that we would do. And so that would be one  
11 of those issues that we would take into account.

12           Certainly good process control over time  
13 is what we're gearing for. The serotypes provide us  
14 an additional piece of information.

15           MS. JOHNSON:       Trisha Marsh Johnson,  
16 Veterinary Environmental Technical Solutions. I'm  
17 concerned about what the Agency intends to do with the  
18 antimicrobial-resistant pattern monitoring given that  
19 1, the presence of antimicrobial-resistance genes does  
20 not indicate process control, and 2, given the fact  
21 that when you look at the antimicrobial-resistance  
22 patterns for *Salmonella*, those basically are (the)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 antibiotics that are used in human medicine.

2 They are not antibiotics that are used in  
3 poultry. And so therefore, most processing  
4 establishments would have absolutely no way to  
5 influence the antimicrobial-resistance patterns of  
6 what's present.

7 DR. ENGELJOHN: And thank you for that  
8 comment. It certainly is something that -- we as an  
9 Agency are interested in feedback from you as  
10 stakeholders to provide us guidance on what you think  
11 would be appropriate action. But from the perspective  
12 of the Agency, we've found that we can no longer just  
13 be looking at a pathogen, *Salmonella*, first of all,  
14 and then taking it as a positive/negative.

15 We really do need to be looking more at  
16 what is coming into the facilities that are being  
17 regulated, and are the establishments doing something  
18 about that for which they have control over. And so  
19 the issue becomes -- maybe in broilers the  
20 significance of antimicrobial resistance may in fact  
21 be different than what it is for turkeys or for dairy  
22 cattle.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1                   And so I think it's pieces of information  
2                   that provide us better information to assess what's  
3                   coming into the human food supply and then what's  
4                   happening in terms of human illness. These are things  
5                   for which I think we set the stage now to say that  
6                   we're looking into better using information and  
7                   providing that to the establishments.

8                   So we don't have any definite answers as  
9                   to what we do when we find the antimicrobial  
10                  resistance. These are case-by-case things that we'll  
11                  take into consideration. But we do think that you as  
12                  an industry need to take this into account.

13                  MR. LINK: Can I ask a question from over  
14                  here?

15                  DR. ENGELJOHN: Yes.

16                  MR. LINKS: Is that okay? It's Charles  
17                  Link with Cargill. The actions that were just kind of  
18                  outlined by Dr. Bennett appear to be obviously focused  
19                  on broilers, but there's mention of turkeys and  
20                  starting to do some turkey testing, swab testing on  
21                  turkeys.

22                  How do plan to catagorize turkey plants?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 Have -- I guess you've give that some thought. But  
2 just -- you don't have a lot of data right now, I  
3 guess.

4 DR. ENGELJOHN: That's true. We don't  
5 have a lot of data to work from, and we're starting  
6 now to collect that information. And we would welcome  
7 any information you as an industry would provide to  
8 us. Again, the sharing of data is critical.

9 But from our perspective within the  
10 Agency, we have looked at the classes of products that  
11 we regulate and that we already have information for.

12 We believe that there are similarities across the  
13 product classes when we segregate them into three  
14 categories. And process control is something that  
15 obviously has some consistency or at least some  
16 comparability across the product classes.

17 But you should expect for the turkey  
18 class, which we're going to begin routinely testing as  
19 we do for most of the other raw-product classes, that  
20 this should be considered to be a baseline year of  
21 assessing that information and then moving forward  
22 from there.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           We did lay forward in the Federal Register  
2 document a process by which -- at the moment we  
3 consider we will look at in terms of categorizing  
4 establishments. And that would be at least having  
5 enough information from a sample set -- more than just  
6 one sample set to make a decision, because we're  
7 looking for that consistent, persistent process  
8 control.

9           So we did actually identify it in the  
10 Federal Register document that it -- initially,  
11 anyway, we'll be looking at the two most recent sample  
12 sets that we have. For the poultry classes, broilers  
13 right now I think is at 51 consecutive days of  
14 information. And for turkeys, I believe it's 59 days  
15 consecutively. So that gives us a picture over a  
16 period of time.

17           Yes, Dane.

18           MR. BERNARD: Thanks, Dan.

19           I think I'm still a little confused, if  
20 you will. Stan's question about the serotypes and the  
21 other question about the antibiotic resistance -- and,  
22 you know, obviously the Agency is interested in

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 process control at the centerpiece. And you're  
2 concerned about other factors as well.

3 But if we're to comment on the rule, I  
4 think we need some other idea or some more idea as to  
5 how that information might play into classification or  
6 what it is you may intend to do with it.

7 And, you know, Stan's question was the  
8 same question I have -- is if you have -- if you're  
9 below the 50 percent level in performance, but the  
10 majority of your isolates happen to be a strain of  
11 concern, where does that leave you?

12 And I think -- more important for us to  
13 look at our own operations in terms of where the  
14 Agency may want this issue to lead. What should we be  
15 testing for? Serotyping is not an inexpensive thing.

16 We're not used to doing that routinely. It can be  
17 done.

18 Running antibiotic resistance patterns --  
19 is not something that I would think too many of us  
20 have an idea of what profiles we're running. So I  
21 think we would love to have a little bit more insight  
22 into where the Agency is thinking in these regards,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 because it will help to guide us in terms of what we  
2 need to be prepared for.

3 DR. ENGELJOHN: Dr. Raymond.

4 DR. RAYMOND: For those who may have been  
5 multitasking during Sean's presentation yesterday,  
6 I'll remind you that in his presentation, for those  
7 plants that fell consistently into the category of six  
8 or fewer positive tests, less than 50 percent, they  
9 gave them a baseline for how many of their samples  
10 would contain human pathogens.

11 For those plants that fell into the second  
12 category, between seven to 12 positives, we saw a  
13 ninefold increase in *Salmonella* human pathogens. And  
14 for those that fell into the third -- I think it was a  
15 thirteen-fold increase.

16 So to give you some reassurance, Dane, if  
17 your plant is having six or fewer positive samples,  
18 the chance that those samples are going to have five  
19 that contain human -- but we just have not seen that.

20 But if we did see that five out of the six  
21 contained Enteritidis, probably we would take  
22 different action with that particular plant than

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 perhaps a plant that had eight positive samples, but  
2 they're all Kentucky. We will individualize based on  
3 the risk to humans.

4 But we saw a tremendous increase when you  
5 went from six to seven to 12 samples positive.

6 DR. ENGELJOHN: Dr. Masters.

7 DR. MASTERS: Just to be a little bit  
8 clearer, I think what we're saying at this point as an  
9 Agency, for our intent and purposes as we start out,  
10 we would put you in category 1 regardless of the  
11 serotype. So if you had six or fewer and they were  
12 all Kentucky, we would put you in category 1, to be  
13 very clear to Stan's question.

14 We are interested in your feedback as to  
15 how you would perceive how we should use the  
16 categories. But that's how we would start out. We  
17 will be providing you serotype data as we receive that  
18 information to assist you as an industry in what's  
19 useful.

20 We have found that the most -- obviously,  
21 because there's more *Salmonella* in categories 2 and  
22 3 -- obviously there's more *Salmonella* of human

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 serotypes of concern in categories 2 and 3, which is  
2 why we prefer all of the plants to be in category 1,  
3 which is why we're trying to drive plants to category  
4 1.

5 But we are interested in providing you  
6 that information, as well as antimicrobial-resistance  
7 information, because as you heard Dr. Huffman say, we  
8 don't want to be in a situation further down the road  
9 that you're working in a vacuum of data.

10 And so we are trying to provide that  
11 information now, because we recognize as we move  
12 forward those are going to continue to be questions on  
13 the forefront. And so we're trying to provide  
14 information now, because we recognize antimicrobial  
15 resistance as a topic that is not going away.  
16 Serotype information is a topic that's not going away.

17 So we're trying to provide you as much  
18 data as we can as an industry to be useful to you.  
19 But as we do categories, we're not going to categorize  
20 you based on your serotype, but on your sheer numbers  
21 of *Salmonella* at this point. But we welcome your  
22 feedback.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           As we determine which plants to do food-  
2 safety assessments in before you exceed the standard,  
3 we may take into consideration whether or not those  
4 were Kentucky or whether or not they were serotypes of  
5 human concern, because we have x number of resources.

6       So it may help us determine where to do a food-safety  
7 assessment.

8           But at this point, for our purposes, we're  
9 going to do categorization based on the actual numbers  
10 of positives. But we certainly welcome feedback on  
11 the total Federal Register package that we've laid  
12 out. But we will do it based on raw numbers at this  
13 point, if that's helpful.

14           DR. ENGELJOHN: Next question.

15           As she's walking up to the phone, I  
16 also -- this is Engeljohn -- just point out that the  
17 whole approach here is to take some preventative  
18 approach to addressing the issues of process control  
19 as opposed to waiting until there's failure and then  
20 stepping in.

21           We've found that we need to change our  
22 process. And this really is about how the Agency is

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 going to redirect its resources.

2 Yes, the questioner.

3 MS. NESTOR: Felicia Nestor, Food and  
4 Water Watch. Two questions. Are -- is FSIS  
5 considering publishing the fingerprints on the  
6 website? I see you're going to share them with  
7 public-health agencies. What about on the website?

8 DR. ENGELJOHN: I think that's an issue  
9 for which -- clearly, getting that into the record is  
10 something that the Agency had anticipated that we  
11 didn't include in that particular document, because  
12 there are issues related to how we want to go forward.

13 But from the perspective of the Agency,  
14 our goal will be to be as transparent as possible and  
15 to provide as much information as possible. And as we  
16 develop that particular process and the mechanisms  
17 associated with it, we'll take that into account.

18 But our goal is to make information  
19 available that's timely so that the industry can react  
20 to it and so that our public-health partners can also  
21 be aware of it.

22 In a preventative type of approach, we

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 would like to be in the position of preventing a food-  
2 borne outbreak by alerting our public-health partners  
3 that in a particular region or in a particular area of  
4 the country or at a particular period of time, we're  
5 seeing an increase in a pathogen that may in fact  
6 present a special concern, so that the public-health  
7 individuals in those areas may in fact determine to  
8 start culturing where they may not before.

9 So the whole issue here is to get the  
10 information out so that we can have better attribution  
11 so that we can prevent food-borne illness rather than  
12 reacting to one that's already occurred.

13 MS. NESTOR: Thank you. Second question  
14 is in regards to the positive incentive of allowing  
15 increased line speeds at a plant that's performing  
16 well. How do you intend to increase line speeds given  
17 the current -- I think it's a requirement that  
18 inspectors can look at 33 chickens per minute or  
19 something like that.

20 Will you add another inspector, or are you  
21 talking about more plants transitioning into HIMP?

22 DR. ENGELJOHN: This is Engeljohn from

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 FSIS. I would say on that issue -- and we did  
2 actually use wording in the document to make very  
3 clear that we don't have this already predetermined as  
4 to how it will work. We're looking to see what the  
5 industry thinks would work, first of all, what the  
6 consumers think would work, what employees think would  
7 work or shouldn't work.

8 The issue really is to focus on  
9 performance -- and that if the public health is in  
10 fact better protected and that we have a system in  
11 place that's delivering food safety in a manner that  
12 is enhanced -- then our issue is that the inspectional  
13 procedure should not inhibit innovation.

14 We would take it into account, whatever  
15 the industry may want to study. And we will at least  
16 study those issues collectively and have answers to  
17 them before we just do it. So the issue is to make  
18 clear we don't already have -- we have not already  
19 decided what is going to be acceptable or not.

20 We want to know what is on the minds of  
21 those that are affected and then figure out a way to  
22 make it work.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 MS. NESTOR: Okay. Thanks.

2 DR. ENGELJOHN: Dr. Masters.

3 DR. MASTERS: Felicia, I would just offer,  
4 because we have a, you know, significant amount of  
5 time to look at this process, we've indicated that  
6 we'd look at a year's worth of data. Depending on the  
7 types of comments that we get, this is something that  
8 we may choose to put through our third-party process  
9 moving forward.

10 So it will certainly depend on the types  
11 of comments that we get. And I'd suggest to everybody  
12 in the room and on the netcast to certainly take that  
13 into consideration. And we welcome any types of  
14 comments, both on the positive incentives as well as  
15 the other incentives as we move forward.

16 And depending again on the substantive  
17 types of comments that we receive, we would be open as  
18 we move forward to looking at the third-party process  
19 as a means of getting comments on the comments that we  
20 receive moving forward.

21 DR. O'CONNOR: Yes. I just had a question  
22 on timing. Dr. Bennett said the actions are to go

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 into effect immediately. So in terms of categorizing  
2 the different processing plants, does that occur based  
3 on historical sample sets, or is that going to happen  
4 after your next sample set?

5 DR. ENGELJOHN: I -- and that's -- this is  
6 Engeljohn with the Agency. And the issue for that is  
7 that we have looked at the 2005 data. So as -- just  
8 so we know where things were in 2005. And we have put  
9 together a team that's making a recommendation back to  
10 management officials within the Agency to decide how  
11 do we need to go forward.

12 I think Dr. Masters mentioned that at the  
13 moment, we just -- we consider everyone at the moment  
14 to be in category 1 as we move forward. The issue  
15 isn't to automatically put you into a position of  
16 punitive measure. We want to start from this day  
17 forward with a means by which we improve process  
18 control.

19 And so I think you should consider the  
20 fact that the actions listed in the document are FSIS  
21 resource specific. And it really is a direction for  
22 us to start the process of making more transparent how

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 we move forward.

2           You should expect that there will be  
3 policy documents that issue over the course of time  
4 that will make clear how we're doing various things.  
5 So from the perspective of saying, "Are we going to  
6 wait until the comment period is over before we do  
7 something," no. We're -- we've already started the  
8 process of looking at how we go forward.

9           As quickly as we issue a directive on the  
10 inspectional procedures for swabbing turkeys, we will  
11 begin swabbing turkeys, as an example.

12           DR. O'CONNOR: Thank you.

13           DR. ENGELJOHN: Yes. Loren Lange, with  
14 the Agency.

15           MR. LANGE: Yes. Hi. This is Loren Lange  
16 from OPHS and FSIS. Back to yesterday. I just wanted  
17 to follow up on questions at the end of the day about  
18 rinsates and TSP and pH.

19           And I tried this morning to get -- we have  
20 two microbiologists that have been following and  
21 continue to follow and will continue to follow this  
22 issue very closely. Unfortunately -- I wanted to get

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701



1 one on the phone, but one's recovering from surgery,  
2 and the other one's at the doctor's office this  
3 morning. So I'm what you get.

4 But I was able to put together -- is that  
5 our microbiologists continue to have a high level of  
6 confidence in our ability to consistently recover  
7 *Salmonella* from our rinsates. And this is really  
8 based on three factors.

9 It's buffering capacity. It was mentioned  
10 we use a 400 milliliter buffered peptone water  
11 solution. The dilution factor that -- it's 400  
12 milliliters -- and that we are sampling after drip  
13 lines so that the amount of fluid that remains on the  
14 carcass has been decreasing.

15 And I want -- a couple other things to  
16 point out. I mean, this method was developed when we  
17 put this program in place for the specific purpose of  
18 being able to maintain pH relatively consistently in  
19 the pre-enrichment phase under a wide variety of  
20 conditions.

21 And it does have a very high level of  
22 buffering capacity. Our labs were able to send me a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 piece of data that at one time they tested that 60  
2 milliliters of a very alkaline solution, 9.72 pH --  
3 and it didn't raise the pH of the 400 milliliters even  
4 a whole point.

5 It raised it from 7.09 to 8.03. And eight  
6 is certainly well within the range that the literature  
7 would indicate *Salmonella* tolerate. It's -- their  
8 optimum growth is 6.5 to 7.5, as the staff says. But  
9 they tolerate up above nine. So thank you.

10 DR. ENGELJOHN: Thank you.

11 Dr. Raymond.

12 DR. RAYMOND: I just -- since there's  
13 nobody else going to ask a question, for those who  
14 knew Loren, I just have to point out that was -- was  
15 that one last thing?

16 DR. ENGELJOHN: I don't see any other  
17 hands. Could we ask on the phone if there's any  
18 questions?

19 Yes. Dane Bernard.

20 MR. BERNARD: Dane Bernard with Keystone.  
21 I was probably multitasking at the moment. If I  
22 could ask for maybe a little bit more of the intent of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 the guidance which is -- which you're going to work on  
2 as soon as you get back, I know. But -- don't rush on  
3 our account. But --

4 DR. BENNETT: I've already started, Dane.  
5 It's too late.

6 MR. BERNARD: -- give us just some idea of  
7 the intent of the guidance.

8 DR. ENGELJOHN: Yes. The -- and Patty,  
9 please correct me if I get your assignment wrong.

10 But the issue with regards to the guidance  
11 is that we recognize -- particularly the presentation  
12 that Dr. Laura Hulseley made yesterday, which walks you  
13 through the entire slaughter-dressing process and  
14 identified the points at which, from a literature  
15 review -- that our technical-service-center experts  
16 had conducted points at which there are in fact known  
17 effects with regards to intervention controls.

18 And I think it's fair to say that the  
19 document that we're working on will take that  
20 information and put it into a form that is easily  
21 followed in terms of following the points and  
22 understanding the information as well as providing a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 literature review.

2 And so the first process here will be to  
3 capture the information from that presentation, which  
4 is a rather extensive literature review on the issues  
5 at slaughter dressing, and then as we've captured  
6 information from this meeting, get in additional  
7 information from the industry.

8 As we get the transcripts back and the  
9 questions and answers that can in fact answer  
10 questions within the document, we will modify that  
11 compliance guideline over time.

12 Our intention is to provide compliance  
13 guideline in an effort for industry, particularly  
14 small businesses, to be able to understand how to take  
15 the science related to an issue and practically apply  
16 it. So it really will be a walk through the  
17 slaughter-dressing process with a literature review  
18 associated with it as a first cut. Okay.

19 There were no questions on the phone and  
20 no more questions in the room.

21 Well, I do want to encourage all of you to  
22 submit your written comments to the Agency. I believe

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you have 90 days to do so. And I would say, as we  
2 pointed out in the document -- the Federal Register  
3 document, we're going to study this at least for the  
4 course of this next full year in order to see what  
5 progress we see.

6 We have a particular interest in the  
7 change from categories 3 and 2 down to category 1, but  
8 we certainly will take your input into the assessments  
9 that we're making about this policy. We want this  
10 policy to work, and we know we need to work with you  
11 to do so.

12 And so the goal here will be to -- we'd  
13 like to get your comments within the next 90 days.  
14 We'll accept that at any time. I should always say  
15 that. Even though a comment period closes, we as an  
16 Agency are open to input as you generate it.

17 So if I could then, I'm just going to  
18 start into my presentation, and then we'll wrap up  
19 this morning. Oh, I'll get the lights. I can  
20 multitask. And for those of you who don't know me,  
21 I'll introduce myself here at the end of the  
22 presentation, but -- at the session that we've had

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 here.

2 But I've -- my name is Daniel Engeljohn.  
3 I have about 25 and a half years or so experience with  
4 USDA, both with the agriculture and marketing service  
5 and with FSIS. My major issues within the Agency,  
6 particularly over the last 15 years or so, have been  
7 in process, products and policy development.

8 So my responsibilities in the Agency are  
9 developing the regulations, the directives and notices  
10 that guide our -- you know, our inspectors on their  
11 daily activities. So I'm within the policy office.

12 And my educational background is in animal  
13 science and meat science and mycobiology, as well as  
14 human nutrition.

15 I'm going to summarize the meeting for you  
16 as I saw it occurring over the last day and a half.  
17 On day 1, we had some presentations related to the  
18 purpose and the background, the reason why we need to  
19 have this meeting at this time, and to start the ball  
20 rolling on making changes within the behavior of the  
21 industry, as well as how the Agency utilizes its  
22 resources.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1           So we talked about the original pathogen-  
2 reduction strategy. Really, what was -- the final  
3 role was really the stimulator here. You received  
4 information about the most current *Salmonella* data  
5 from 2005, which I understand should be made available  
6 by the Agency by the time we close here.

7           We talked about the new risk-based focus  
8 on pathogen reduction in broilers. This really was  
9 why did we select the categories that we did,  
10 categories 1, 2 and 3.

11           We had an excellent presentation on using  
12 evidence-based information to address what research  
13 has been done and how effective is it through the  
14 systematic review of intervention strategies.

15           And then we got an extensive overview of  
16 the poultry-slaughter process, which will be  
17 translated into a compliance guideline within days as  
18 opposed to weeks that would be available to the  
19 industry.

20           And our goal within the Agency will be to  
21 ensure that every plant has a copy of that information  
22 and that our employees do as well, as well as provide

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 you the public a means by which you can request that  
2 information. So that information you should find out  
3 about through our constituent updates. So we'll make  
4 that information known as to how you can obtain a  
5 copy.

6 And then you got a summary of the food-  
7 safety assessment report on vulnerabilities that we as  
8 the Agency have found have been those issues within  
9 the food-safety systems that we have found not being  
10 attended to that, when attended to, tend to result in  
11 establishments having control over their pathogens.

12 In the afternoon -- began the process of  
13 having an ante-mortem controls overview where we  
14 looked at pre-harvest issues, environmental  
15 considerations, and particularly small-plant concerns.

16 And we as an Agency are always looking at what we  
17 need to do to address small-plant concerns, not only  
18 for the industry itself, but for our employees that  
19 are employed within those facilities.

20 Our goal is to ensure that the guidance  
21 that we make available to the industry can in fact be  
22 applied by the individuals with the least amount of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701



1 resources so that we are actually giving them the how-  
2 to to meet the expectations of the Agency.

3 And then we got an overview of the  
4 slaughter-dressing controls related to the scalding,  
5 defeathering, evisceration, chilling, and grinding,  
6 and the effectiveness of antimicrobial interventions.

7 Today then we had a summary of  
8 presentations related to industry perspectives. And I  
9 think you got an excellent overview of what has worked  
10 within the industry, particularly within the poultry  
11 industry, as well as some of the activities that are  
12 going on right now in order to better characterize the  
13 effectiveness of the food-safety systems.

14 And then, I think importantly, we all got  
15 to hear what the beef industry considers to be their  
16 perspective as to what worked with regards to  
17 ultimately gaining control over *E. coli* 0157 in beef.

18 And we as an Agency are in concurrence with the  
19 industry in that together --I think both of us work  
20 together to ensure that we in fact had a real positive  
21 impact on public health.

22 And I think our message to you as an

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 industry as well, beyond just beef, is that we're at  
2 the beginning stages now with regards to *Salmonella*  
3 control where we need to work together to make this  
4 work.

5 And then you got a perspective from FSIS  
6 on our next steps, the current thinking that we're  
7 going to be pursuing with regards to how we want to  
8 ensure that there's better process control with  
9 regards to *Salmonella* particularly.

10 But I do want to point out that although  
11 we have had a focus on *Salmonella*, we also have issues  
12 with regards to *Campylobacter* as well as other  
13 pathogens that need to be controlled within the food-  
14 safety systems.

15 And I think you will find in the future  
16 that we won't be just looking at one pathogen, one  
17 process. We really need to collectively know what's  
18 happening in the food-safety systems with regards to  
19 the pathogens of public-health concern.

20 And from the Agency's perspective, we --  
21 and part of my job specifically is to ensure that  
22 whatever policies we put in place are measurably

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 having an impact, and in this case, on exposure of the  
2 public to pathogens of public-health concern -- but  
3 most importantly, as we get better attribution data,  
4 that the public health is in fact being better  
5 protected to food safety.

6 I have some take-home messages, three that  
7 I want to just reinforce as you leave today.  
8 Effectiveness of *Salmonella* control will closely  
9 mirror the continued focus that we've had on beef for  
10 *E. coli* 0157:H7 control.

11 I don't want anyone to believe that we're  
12 going to step down our focus on *E. coli* 0157 in beef  
13 or in any other product for which we find it emerging.

14 We have the resources and capability to ensure that we  
15 continue to focus on this particular pathogen and that  
16 we don't lose the progress that was in place.

17 Having said that, we also want to ensure  
18 that we use our resources in a way that we can address  
19 other problems. And we consider *Salmonella* in all  
20 classes of products to be a problem.

21 Our initial action will be on broiler  
22 carcasses because of the persistent upward trend that

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 we've seen there. We're going to follow that up as  
2 quickly as we can with beginning to test turkey  
3 carcasses -- and to begin establishing a baseline for  
4 where we are in that particular product class.

5 And I do know that the industry has done  
6 some baseline studies within maybe the older  
7 broiler -- or older turkey classes. And the Agency  
8 has not received that information. But I'm inviting  
9 you as an industry on any of these raw-product  
10 classes -- that if you have information that  
11 collectively you want to submit as an industry, you  
12 should consider doing that.

13 The Agency is trying to find ways to work  
14 with you on the data that you have so that we don't  
15 use it against you, as many of you have often in the  
16 past felt that the sharing of data resulted in  
17 punitive measures. And we're trying to overcome that  
18 by demonstrating that we can assess the information  
19 you have and work together to enhance public health.

20 We also have problems in hog carcasses. I  
21 just want to reiterate that there has been an increase  
22 in the hog-carcass classes with regards to *Salmonella*,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 although it's been erratic. It's been up and then  
2 down. But we do have an interest in focusing there as  
3 well.

4 And then more importantly with the ground  
5 products -- because the highest prevalence or at least  
6 the percent positives that we're finding is in the  
7 ground products. And it's the source materials that  
8 we want to focus on first, and then we'll focus on  
9 those ground products.

10 And the *Salmonella* when we're dealing with  
11 raw products -- unlike 0157:H7, which we know  
12 undercooking was a problem -- we do know that with the  
13 raw classes of products, that cross contamination of  
14 the raw products can in fact be a major pathway by  
15 which people are transferring the organisms onto other  
16 surfaces or other foods.

17 And so just fully cooking the product  
18 isn't going to take care of the issues with regards to  
19 *Salmonella* on raw products.

20 The second take-home message I want to  
21 leave you with is that the industry-wide shift to  
22 category 1 level process control for *Salmonella* is

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 expected to be timely. We as an Agency have set  
2 forward some markers, or at least we put in the  
3 document that we'd like to have 90 percent of the  
4 industry in category 1 this next year.

5 We'd like to see what the industry is  
6 going to do to gather information that they're going  
7 to share with each other, as well as to enhance their  
8 food-safety systems to address this issue. We think  
9 it is necessary to have a timely response.

10 The public-health benefit regarding  
11 reduced exposure to serotypes causing common human  
12 illness will be more closely tracked. We in fact are  
13 telling you that we believe that, although we're  
14 looking at *Salmonella* process control, we in fact are  
15 looking at those serotypes that are causing human  
16 illness.

17 We're working with CDC and other public-  
18 health partners to ensure that we are in fact having a  
19 major impact on public health with regards to control  
20 for *Salmonella*.

21 And then finally, we expect to seek a  
22 means to continue the dialog with all the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1 stakeholders. This will ensure that we have  
2 continuous improvement for the control of *Salmonella*  
3 and other pathogens of public-health concern in raw  
4 products.

5 We don't have any set and firm decision  
6 made as to how we're going to move forward, other than  
7 we've told you we're getting control over the  
8 resources that we have within the Agency as to how we  
9 are going to be looking at the industry's control with  
10 raw-product classes.

11 But we're open to hear from you how you  
12 think things would work better. What incentives do  
13 you think would provide you the appropriate means to  
14 justify the added expense of having a measurable  
15 impact on reducing pathogens of public-health concern?

16 If you have concerns other than production  
17 volume and you think that there are other things that  
18 would encourage you within the industry to actually  
19 expend the resources to have better process control,  
20 we want to know what those are.

21 And we'll find a way to work with you on  
22 ensuring that our regulatory process is not an

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

1       impediment to innovation.

2                   Those are the three messages I wanted to  
3       leave you with. We're open to hear from you. We've  
4       heard 28 speakers in a day and a half. And I want to  
5       thank all the speakers. Every one of you did in fact  
6       stay within your time frame.

7                   I think every one of you gave us valuable  
8       information. I myself learned a great deal. I hope  
9       you did as well. We will capture this information and  
10      make it available to you as quickly as we can. And I  
11      thank all of you for your participation. Have a safe  
12      trip home.

13                   (Applause.)

14                   (Whereupon, at 11:45 a.m., the meeting was  
15      concluded.)

16

17

18

19

20

21

22

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701